

3.2.3 Grants for research projects sponsored by the government and non-government agencies during the year (INR in Lakhs)

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Government/Non-Government)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project
Pattern of care and survival studies- cervix cancer	Dr. Amita Maheshwari	NCRP, ICMR	Government	Medical and Health Sciences	2006	6.75	19 Years
Pattern of care and survival studies Breast cancer	Dr. Rajesh Dikshit	NCRP, ICMR	Government	Medical and Health Sciences	2006	6.75	19 Years
Pattern of care and survival studies Head and Neck cancer	Dr. Rajesh Dikshit	NCRP, ICMR	Government	Medical and Health Sciences	2006	6.75	19 Years
A randomized trial of concurrent versus sequential Tamoxifen with radiotherapy to assess the extent of pulmonary fibrosis and disease related control and survival in breast cancer patients	Dr. Ashwini Budrukkar	Indian Council of Medical Research	Government	Medical and Health Sciences	2007	9.88	15 Years 9 Months 2 Days
Post-Mastectomy Radiation Therapy in High Risk, Node Negative women with Early Breast Cancer (PMRT-NNBC)	Dr. Tabassum Wadasadawala	DST-SERB	Government	Medical and Health Sciences	2016	159.74	12 Years
Peripheral T--Cell Lymphoma: Impact of Immunophenotypic subsets, cytogenetic abnormalities, microenvironment and PI3K/NFKB on behavior	Dr. Tanuja Shet	DEPARTMENT OF BIOTECHNOLOGY	Government	Medical and Health Sciences	2017	135.98	6 Years
Radiation Dose Optimization in Diffuse large B- cell Lymphoma - A Randomised Phase III non- inferiority trial.	Dr. Jayant Goda	DST-SERB	Government	Medical and Health Sciences	2016	66.90	7 Years
Biological effect of low and high dose radiation exposure on human peripheral blood mononuclear cells and tumour tissues of cancer patients: a prospective in-vivo study	Dr. Rajendra Badwe	DEPARTMENT OF ATOMIC ENERGY	Government	Medical and Health Sciences	2017	398.18	6 Years
Assessment of changes in hypoxia related biomarkers during surgery in resectable non-small cell lung cancer	Dr. Sabita Jiwnani	DEPARTMENT OF ATOMIC ENERGY	Government	Medical and Health Sciences	2016	36.10	6 Years
Low Cost Companion Diagnostic Test for Predicting Benefit of Adjuvant Chemotherapy in ER+ Breast Cancer	Dr. Vani Parmar	DST (Indo US, Endowment Fund)	Government	Medical and Health Sciences	2016	142.89	7 Years
Role of IL-9 and Th9 cells in T cell lymphoma with cutaneous involvement	Dr. Hasmukh Jain	ICMR+ IIT-BOMBAY	Government	Medical and Health Sciences	2017	3.02	6 Years 6 Months
BIONIC: Big Imaging Data Approach For Oncology in a Netherlands India Collaboration	Dr. Venkatesh Rangarajan	DEITY-Dept of Electronics Govt of India	Government	Medical and Health Sciences	2017	44.25	8 Years
Reverse swing-M : Repurposing of Mebendazole in recurrent glioblastoma.	Dr. Vijay Patil	Indian Council of Medical Research	Government	Medical and Health Sciences	2017	47.98	5 Years
A phase II trial to study efficacy, toxicity and immunomodulatory effect of Carcol-S in high grade serous epithelial ovarian cancer at first serological relapse	Dr. Amita Maheshwari	MINISTRY OF AYUSH,CCRAS,GOVT OF INDIA	Government	Medical and Health Sciences	2018	98.40	5 Years
A dosimetric and clinical study of DIBH in Mediastinal Lymphomas: An exploratory observational study	Dr. Jayant Goda	DST	Government	Medical and Health Sciences	2018	56.92	14 Years
An integrated network analysis to identify genomic alteration profiles of human periampullary cancer	Dr. Shailesh Shrikhande	Department of Biotechnology, Government of India	Government	Medical and Health Sciences	2018		5 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 24.27
 HOD / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मंडई - 400 084

Compilation of data as received from Dean-Academic of the

Genome-Wide Association Study to Identify Role of Genetic Susceptibility in Buccal Mucosa Cancer.	Dr. Sharayu Mhatre	Indian Council of Medical Research	Government	Medical and Health Sciences	2018	297.80	4 Years
Assessing Trop2 expression and its correlation with the anti-Trop2 immune status in ovarian cancer patients	Dr. Amita Maheshwari	Indian Council of Medical Research	Government	Medical and Health Sciences	2018	21.00	5 Years
Tumor Suppressors and Oncogenes: From Endometrial Cancer Cell Lines to Endometrial Cancer Tissues	Dr. Bharat Rekhi	Indian Council of Medical Research	Government	Medical and Health Sciences	2019	5.00	3 Years 4 Months
Development and Validation of an Electronic Surveillance System for Surgical Site Infections Developing During Hospital Stay and After Discharge: A Multi-Centric Study	Dr. Sheila Myatra	Indian Council of Medical Research	Government	Medical and Health Sciences	2018	25.19	4 Years
Genomics for Public Health in India (IndiGen): a Tongue Cancer Initiative	Dr. Amit Dutt	CSIR-Institute of Genomics and Integrative Biology (CSIR IGIB)	Government	Medical and Health Sciences	2019	907.80	2 Years 3 Months
Primary screening of high risk HPV DNA by a low cost molecular HPV test for early detection of cervical precancers and cancers among women in urban and rural community of Maharashtra	Dr. Sharmila Pimple	Department of Health Research (DHR)	Government	Medical and Health Sciences	2019	92.54	3 Years
Role of toll-like receptors and TLR agonists in modulating response to chemotherapy in TNBC patients	Dr. Shalaka Joshi	Department of Biotechnology	Government	Medical and Health Sciences	2020	41.13	3 Years 3 Months
Total Marrow and Lymphoid Irradiation (TML) as conditioning regimen for peripheral stem cell transplant in high risk/ relapsed /refractory leukemias.	Dr. Jayant Goda	CSIR	Government	Medical and Health Sciences	2019	61.31	5 Years
The effect of resveratrol and copper on mortality in patients with hematological malignancies presenting with febrile neutropenia and sepsis or septic shock admitted to intensive care unit. A pilot study	Dr. Amol Kothekar	Indian Council of Medical Research	Government	Medical and Health Sciences	2020	7.61	3 Years
Investigating Human Papillomavirus (HPV) Infection and HPV-associated Disease in Indian Men who have Sex with Men who are HIV-positive	Dr. Sharmila Pimple	Indian Council for Medical Research (ICMR)	Government	Medical and Health Sciences	2021	56.22	1 Years
Role of water pollution in development of esophageal cancer: a case-control stratified by high and low risk regions.	Dr. Rajesh Dikshit	Department of Health Research	Government	Medical and Health Sciences	2020	65.80	3 Years
Evaluation of the role of the immune cell profile in the persistence of minimal residual disease and dynamics of the relapse in childhood T-cell lymphoblastic leukemia: a prospective observational study.	Dr. Prashant Tembhare	Indian Council of Medical Research	Government	Medical and Health Sciences	2020	46.56	3 Years
Assessment of Prakriti (Ayurvedic body constitution) of patients with Cervical and Ovarian cancers	Dr. Amita Maheshwari	Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Govt. of India, New Delhi	Government	Medical and Health Sciences	2021	7.81	1 Years 6 Months
Development of a Multi-omics based Neoantigen Discovery Platform to generate Personalized Vaccines for Gliomas	Dr. Sridhar Epari	Indian Council of Medical Research	Government	Medical and Health Sciences	2020	27.20	3 Years

Compilation of data as received from Dean, Academic of the various P/C Sem in HBNZ

प्रो. पी. सी. सेल्किन / Prof. P.C. Selkin
कुलसचिव / REGISTRAR
सिंधुभाषा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
राक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
School Complex, Anushakti Nagar, Mumbai - 400 094

Integration of Extended Immune Monitoring (ExImm) and clinical parameters for early prediction of disease trajectory/progression, treatment planning and prophylaxis to improve COVID-19 prognosis: Immunoprofiling Consortium by Indian Council of Medical Research (ICMR)	Dr. Prashant Tembhare	Indian Council of Medical Research (ICMR)	Government	Medical and Health Sciences	2020	97.71	2 Years
A prospective observational study to establish the duration of persistence of replication-competent SARS-CoV-2 in oncology patients with COVID-19 on chemotherapy	Dr. Chetan Dhamne	Indian Council of Medical Research	Government	Medical and Health Sciences	2021	11.75	1 Years 6 Months
A multicenter observational study of candidaemia cases with special reference to Candida auris candidaemia among ICU patients in India	Dr. Sanjay Biswas	Indian Council of Medical Research	Government	Medical and Health Sciences	2022	1.64	1 Years 6 Months
Development and comparison of different training methods for gynecological brachytherapy skills development: A skills and training methodology development and assessment initiative	Dr. Supriya Chopra	DST	Government	Medical and Health Sciences	2021	307.98	5 Years
PRESCRIP-TEC Prevention and Screening Innovation Project Toward Elimination of Cervical Cancer	Dr. Sharmila Pimple	Horizon 2020-DBT	Government	Medical and Health Sciences	2021	75.57	3 Years
Soft- Theorems, S-Matrix and Flat-Space holography	Dr. Shamik Banerjee	Science and Engineering Research Board	Government	Physical Sciences	2020-21	2.2	3 years
Investigating the role of methyl ammonium ordering in apto electronic properties of hybrid perovskites	Dr. Dinesh Topwal	Science and Engineering Research Board	Government	Physical Sciences	2020-21	8.407	3 years
Exploring Radiative Neutrino Masa Models through Dark Matter and Collider Experiment	Dr. Kirtiman Ghosh	Science and Engineering Research Board	Government	Physical Sciences	2020-21	6.61	3 years
Designing thin film heterostructure of quantum materials	Dr. Debakanta Samal	Science and Engineering Research Board	Government	Physical Sciences	2020-21	22.525	3 years
Landscape of Beyond the Standard Model Physics at Neutrino Experiments	Dr. S K Agarwalla	Science and Engineering Research Board	Government	Physical Sciences	2021-22	20	5 years
Scattering Amplitudes and Flat Space Holography	Dr. Shamik Banerjee	Science and Engineering Research Board	Government	Physical Sciences	2021-22	15.1454	5 years
Cluster Project on "Quantum Information Technologies with Photonic Devices"	Pankaj Agrawal	Department of Science and Technology (DST)	Government	Physical Sciences	2019-20	61.66	3 years
SwarnaJayanti Fellowship & research grant	Dr. S K Agarwalla	MINISTRY OF SCIENCE & TECHNOLOGY	Government	Physical Sciences	2020-21	3	5 years
National Post-Doctoral Fellowship in Physical Science	Dr. Sourmya C	Science and Engineering Research Board	Government	Physical Sciences	2019-20	9.6	2 years
Probing Heat Transport phenomena at Nanoscale using Raman Thermometry	Dr. Satyaprakash Sahoo	Science and Engineering Research Board	Government	Physical Sciences	2020-21	7.921	3 years
Stochastic thermodynamics of active particles and fields	Dr. Debashis Choudhuri	Science and Engineering Research Board	Government	Physical Sciences	2020-21	2.2	3 years
INSPIRE Faculty Fellowship Program	Dr. Aparajita Mandal	MINISTRY OF SCIENCE & TECHNOLOGY	Government	Physical Sciences	2020-21	22	5 year
SPG	Dr. Asima Bhattacharyya	Science and Engineering Research Board	Government	Life Sciences	2021-2022	18.50	3 years

Compilation of data as received from Dean-Academic of the various ^{कूलसचिव} REGISTRAR of HBNI ^{होमि भाभा राष्ट्रीय संस्थान} Bhabha National Institute ^{प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४} Training School

Dr. P. C. Selvin / Prof. P. C. Selvin
REGISTRAR of HBNI
होमि भाभा राष्ट्रीय संस्थान
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४

Adhoc	Dr.Debasmita Alone	ICMR	Government	Life Sciences	2021-2022	24.72	3 years
Core Research Grant	Dr.Ramanujam Srinivasan	Science and Engineering Research Board	Government	Life Sciences	2021-2022	20.47	3 years
Core Research Grant	Dr.Tirumala Kumar Chowdary	Science and Engineering Research Board	Government	Life Sciences	2021-2022	15.64	3 years
Core Research Grant	Dr.Anniruddha Datta Roy	Science and Engineering Research Board	Government	Life Sciences	2021-2022	10.40	3 years
Inspire Faculty Fellowship	Dr.Ananya Dasgupta	Department of Science and Technology (DST)	Government	Life Sciences	2021-2022	22.00	5 years
Core Research Grant	Dr.Praful Singru	Science and Engineering Research Board	Government	Life Sciences	2021-2022	18.41	3 years
Teachers Associateship for Research Excellence (TARE)	Dr.Somit Dass under mentorship of Dr. Ritwick Das	Science and Engineering Research Board	Government	Physical Sciences	2021-2022	3.35	3 years
Matrics - Matrics Expert Committee	Dr.Najmul Haque	Science and Engineering Research Board	Government	Physical Sciences	2021-2022	2.20	3 years
Core Research Grant	Dr.Subhankar Bedanta	Science and Engineering Research Board	Government	Physical Sciences	2021-2022	24.07	3 years
Core Research Grant	Dr.Ashok Kumar Mohapatra and Dr.Ritwick Das	Science and Engineering Research Board	Government	Physical Sciences	2021-2022	24.21	3 years
Core Research Grant	Dr.Chidambaram Gunanathan	Science and Engineering Research Board	Government	Chemical Sciences	2021-2022	19.37	3 years
Core Research Grant	Dr.P C Ravikumar	Science and Engineering Research Board	Government	Chemical Sciences	2021-2022	20.90	3 years
Core Research Grant	Dr.Sharanappa Nembenna	Science and Engineering Research Board	Government	Chemical Sciences	2021-2022	26.99	3 years
Start-up Research Grant	Dr.Dipak Samanta	Science and Engineering Research Board	Government	Chemical Sciences	2021-2022	23.92	2 years
Research grant	Prof. A Srinivasan	CSIR	Government	Chemical Sciences	2021-2022	6.09	3 years
Core Research Grant	Dr.Jogendra Nath Behera	Science and Engineering Research Board	Government	Engineering Sciences	2021-2022	11.50	3 years
Matrics - Matrics Expert Committee	Dr.Senthil Kumar Kunju	Science and Engineering Research Board	Government	Mathematical Sciences	2021-2022	2.20	3 years
Start-up Research Grant	Dr.Liton Majumdar	Science and Engineering Research Board	Government	Physical & Mathematical Sciences	2021-2022	14.90	2 years
National Post Doctoral Fellowship	Dr.Rupali Mohanty(NPDF) under the mentorship of Dr.Guneshwar Thangjam	Science and Engineering Research Board	Government	Physical sciences	2021-2022	10.66	2 years
Matrics - Matrics Expert Committee	Dr. Liton Majumdar	Science and Engineering Research Board	Government	Physical sciences	2021-2022	2.20	3 years
INSPIRE Faculty Award	Muna Naik	Department of Science and Technology (DST)	Government	Mathematical Sciences	2021-2022	22.000	5 years
INSPIRE Faculty Award	Pradeep Kumar Rai	Department of Science and Technology (DST)	Government	Mathematical Sciences	2016-2017	16.401	5 years
Science and Engineering Research Board (SERB) - Research grant	Debraj Rakshit	Science and Engineering Research Board (SERB)	Government	Mathematical Sciences	2021-2022	14.663	2 years
Science and Engineering Research Board (SERB) - Research grant	Manoj Kumar	Science and Engineering Research Board (SERB)	Government	Mathematical Sciences	2021-2022	2.200	3 years
Science and Engineering Research Board (SERB) - Research grant	R. Thangadurai	Science and Engineering Research Board (SERB)	Government	Mathematical Sciences	2020-2021	1.000	3 years
Science and Engineering Research Board (SERB) - Research grant	Sudip Chakraborty (SRG/2020/002756)	Science and Engineering Research Board (SERB)	Government	Physical Sciences	2020-2021	17.956	3 years
Science and Engineering Research Board (SERB) - Research grant	Sudip Chakraborty (SRG/2020/001707)	Science and Engineering Research Board (SERB)	Government	Physical sciences	2020-2021	23.860	2 years
Science and Engineering Research Board (SERB) - Research grant	Sudip Kumar Haldar	Science and Engineering Research Board (SERB)	Government	Physical sciences	2020-2021	3.350	3 years
CSIR- SSB Award	Aditi Sen De	CSIR Human Resource Development Group	Government	Physical Sciences	2021-2022	1.800	1 year
CSIR- SSB Award	Pinaki Majumdar	CSIR Human Resource Development Group	Government	Physical Sciences	2021-2022	1.800	1 year
CSIR- SSB Award	Ashoke Sen	CSIR Human Resource Development Group	Government	Physical Sciences	2021-2022	0.518	1 year

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR

Compilation of data as received from Dean Academic of the various departments of HBNZ
HOMI BHABHA NATIONAL INSTITUTE
अक्षय विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०००९४
Homi Bhabha National Institute, Anushakti Nagar, Mumbai - 400094

J C Bose Fellowship	Ashoke Sen	Science and Engineering Research Board (SERB)	Government	Physical Sciences	2017-2018	3.000	5 years
DST – NSM “Mesoscale Modeling of amorphous solids for large scale simulations”	Prof. Pinaki Chaudhuri	DST – NSM	Government	Physical Sciences	2021	53.106	2 years
SERB Start up research grant “First passage of intermittent random walk searchers – applications to statistical physics, biological and chemical processes”	Dr. Arnab Pal	DST – SERB	Government	Physical Sciences	2022	13.58	2 years
SERB – M(atching) A(uction) C(ontract) : Parameterized Algorithms for Economics and Computation	Dr. Sushmita Gupta	SERB	Government	Mathematical Sciences	2022	27.59	3 years
SERB – Game Theory on Stream	Dr. Sushmita Gupta	Science and Engineering Research Board	Government	Mathematical Sciences	2022	6.6	3 years
J C Bose Fellowship	Prof. Gautam Bhattacharyya	DST-SERB	Government	Physical Sciences	2017-2022	2.00	5 years
Core Research Group	Dr. Chandrima Das	DST-SERB (2)	Government	Life Sciences	2019-2022	5.50	3 years
Swarna Jayanti Fellowship	Dr. Chandrima Das	DST-SERB (3)	Government	Life Sciences	2019-2024	57.00	5 years
Core Research Group (IBS)	Dr. Padmaja Prasad Mishra	DST-SERB	Government	Chemical Sciences	2020-2023	2.00	3 years
MATRICES-MATRICES Expert Committee	Prof. Abhik basu	DST-SERB (1)	Government	Physical Sciences	2020-2023	2.20	3 years
Core Research Group (PAC Physics-1)	Prof. Abhik basu	DST-SERB (2)	Government	Physical Sciences	2022-2025	.90	3 years
Start-up Research Grant (EC P&MS)	Dr. Arunava Mukherjee	DST-SERB	Government	Physical Sciences	2020-2023	11.89	3 years
Start-up Research Grant (EC P&MS)	Dr. Debasish Banerjee	DST-SERB	Government	Physical Sciences	2022-2024	9.56	2 years
Core Research Group (IBS)	Dr. Debasish Mukhopadhyay	DST-SERB	Government	Physical Sciences	2022-2025	19.95	3 years
Core Research Group (IBS)	Dr. Oishee Chakrabarti	DST-SERB (2)	Government	Life Sciences	2022-2025	22.96	3 years
Scientific Social Responsibility	Dr. Subhabrata Majumder	DST-SERB	Government	Life Sciences	2021-2023	17.52	2 years
Research & Development Project	Dr. Chandrima Das	DBT (1)	Government	Life Sciences	2019-2022	15.35	3 years
S Ramachandran-National Bioscience Award for Career Development 2019	Dr. Chandrima Das	DBT-NBACD (2)	Government	Life Sciences	2020-2023	5.00	3 years
National Women Bioscientist Award	Dr. Oishee Chakrabarti	DBT	Government	Life Sciences	2019-2024	4.84	5 years
Early Career (Basic Fellowship)	Dr. Subhabrata Majumder	DBT-WT/1A	Government	Life Sciences	2020-2025	21.80	5 years
Raja Ramanna Fellowship Scheme	Prof. Satyajit Saha	Department of Atomic Energy	Government	Physical Sciences	2019-2022	13.17	3 years
INSA Senior Scientist	Prof. Naba Kumar Mondal	INSA	Government	Physical Sciences	2019-2022	3.60	3 years
INSA Senior Scientist	Prof. Bikas K. Chakrabarti	INSA	Government	Physical Sciences	2020-2023	4.60	3 years
INSA Senior Scientist	Prof. Milan Kumar Sanyal	INSA	Government	Physical Sciences	2021-2024	4.60	3 years
Numerical Simulation of deflagration to detonation transition	Ms. Manika Sharma	Terminal Ballistics Research Laboratory, DRDO	Government	Physical Sciences	2018	3.83	2 years 8 months
Plasma Erosion Characterization of Anode linear material	Dr. Mukesh Ranjan	Vikram Sarabhai Space Center, ISRO	Government	Physical Sciences	2019	12.40	2 years
Design and Development of Anti-UAV(Unmanned Aerial Vehicle) system	Dr. Rana Pratap Yadav	Science and Education Research Borad, DST	Government	Physical Sciences	2021	34.87	3 years
Development and validation of Artificial Intelligence Tool for Screening/detection of pulmonary TB and other lung disease using chest X-ray	Ms. Manika Sharma	Indian Council of Medical Research	Government	Life Sciences	2022	6.75	1 year
INSA Young Scientist Research Fellowship	Dr. V. V. Parkar (PI)	INSA, New Delhi	Government	Physical Sciences	2018-2021	15	3 years
BRNS Research project	Dr. V. V. Parkar (PI)	BRNS, DAE	Government	Physical Sciences	2020-2023	22	3 years
DAE-BRNS Project	Dr. Pramod Bhatt (PI)	BRNS, DAE	Government	Physical Sciences	2021	46	3 years
Early Translation Accelerators Funding Scheme	Dr. J.S. Godda (ACTREC) - PI , Dr. A. Kunwar (Co-PI)	BIRAC-DBT	Government	Life Science	2021-2023	199	2 years
37(2)/14/01/2018-BRNS	Dr. Dhanya Sunil (PI) & Dr. R. S. Ningthoujam (PC)	BRNS	Government	Chemical Sciences	2018	32	3 years
58/14/26/2019-BRNS	Dr. Tabssum Khan (PI) & Dr. R. S. Ningthoujam	BRNS	Government	Chemical Sciences	2019	35	3 years
DAE-Science Research Council AwardDr.	Subir Kumar Ghosh	Department of Atomic Energy	Government	Physical Sciences	2015	9.63	5 years
Pattern of care and survival studies- cervix cancer	Dr. Amita Maheshwari	NCRP, ICMR	Government	Medical & Health Sciences	2006	6.75	19 Years

Compilation of data as received from Dean - Academie of the V. K. Rajwade Sanshodhan Mandal, Mumbai

Dr. P. C. Salvin / Prof. P. C. Salvin
 REGISTRAR
 H. B. ROY
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४


Setting up of a Solar Powered Indian Network for Detection of Radon Anomaly for Seismic Alert (INDRA-SA)	Dr. B.K. Sapra	DAE	Government	Physical Sciences	2020	265	3 Years
Processing of Materials and Control of Material Degradation for Nuclear Industry, Zr based, Ni based and Ti based alloys	Dr Vivekanand Kain	DAE	Government	Engineering Sciences	2020	526	3 Years
Development & Deployment of Automation Systems for Security, Surveillance and Imaging	Dr. S Kar	DAE	Government	Engineering Sciences	2020	130	3 Years
Development of improved reactivity control mechanisms and their test facilities	Dr. N. K. Singh	DAE	Government	Engineering Sciences	2020	350	3 Years
Development of Materials, Devices, Analytical Instruments & NDT Techniques for physics Research	Dr. A.K. Chauhan	DAE	Government	Physical Sciences	2020	750	3 Years
R&D in Chemical sciences for Nuclear, Societal and Environmental Applications like Nuclear Safety such as core catcher materials & iodine chemistry, special biosensors, Security related materials and detector materials etc.	Dr. C. N. Patra	DAE	Government	Chemical Sciences	2021	900	3 Years
Newer application of radiation technology for food security and value addition	Dr R. Shashidhar	DAE	Government	Life Sciences	2020	135	3 Years
Augmentation of facilities for Chemical quality control of Nuclear materials and radiochemical research	Dr. P. G. Jaison	DAE	Government	Chemical Sciences	2020	360	3 Years
Development of Synchrotron and Neutron beamlines, optical multilayer devices, liquid hydrogen test loop and Physics Research	Dr. D. V. Udupa	DAE	Government	Physical Sciences	2020	970	3 Years
Deployment of Water Purification Technologies in 50 villages in India	Dr Soumitra Kar	DAE	Government	Chemical Sciences	2020	50	3 Years
Development of new generation alloys (borated steels, RPV steels, zirconium alloys, superalloys etc) for nuclear reactor system and joining technologies for ceramics, metals and special materials	Dr R Tiwari Dr R N Singh. Dr. J B Singh	DAE	Government	Engineering Sciences	2022	569	3 Years
Research in biological systems and their potential biotechnological applications in health and environment	Dr.Bisank Sankar Patro	DAE	Government	Life Sciences	2022	269	3 Years
Setting up of a R&D Facilities at KRUSHAK,Lasalgaon for irradiation of fruits and vegetables	Dr.B. B. Mishra	DAE	Government	Life Sciences	2022	70	3 Years
Isotopes and radiation technologies for industrial and societal applications	Dr. K. A. Dubey Dr. K. Tirumalesh	DAE	Government	Chemical Sciences	2022	305	3 Years
Research and Development on anti-cancer drugs, radiation biology and bio-management of waste water	Dr Santosh Kumar Sandur	DAE	Government	Life Sciences	2022	111	3 Years
Development of Products, Processes and Technologies for Sustainable Agriculture, including setting up of model Seed Villae	Dr. Souframianien J	DAE	Government	Life Sciences	2022	341	3 Years
Augmentation of nuclear medicine services and development of agents for applications in management of tuberculosis and cancer patients	Dr.(Smt.)Savita Kulkarni	DAE	Government	Life Sciences	2022	713	3 Years
Research on cellular and molecular radiation biology for human health	Dr.(Mrs)Anu Ghosh	DAE	Government	Life Sciences	2022	348	3 Years
Augmentation of facilities for enhanced processing of radioisotopes and development of new radiopharmaceuticals & allied products	Dr. Archana Mukherjee	DAE	Government	Life Sciences	2022	190	3 Years
Development of Novel Glass and Ceramic Materials	Dr. Ashok Kumar Arya	DAE	Government	Chemical Sciences	2022	220	3 Years
Development of Freeze & ZLD Desalination Technologies and Advanced Membranes	Dr. A. K. Ghosh	DAE	Government	Chemical Sciences	2022		

Prof. P. C. Selvin /
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
शास्त्र विद्यालय परिसर, अनुशाकती नगर, मुंबई - ४०० ०९४
Institution School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean-
Academic of various CI's/Occ of HBNI

Structural and Thermal Hydraulic Safety Studies for Indian NPP'S	Dr J Chattopadhyay	DAE	Government	Engineering Sciences	2021	540	3 Years
Technology Demonstration of Advanced Chemical Processes and equipments for Nuclear Materials	Dr.S.Mukhopadhyay	DAE	Government	Engineering Sciences	2022	350	3 Years
Research & Development on surface modification using beams & plasma technologies for nuclear & societal application	Dr Namita Maiti	DAE	Government	Engineering Sciences	2022	86	3 Years
Feasibility studies and Demonstration of laser application in medical isotopes	Dr. Jaya Mukherjee	DAE	Government	Physical Sciences	2022	250	3 Years
Augmentation & Upgradation of INDUS beamlines (PX/ECXRD/IR), high pressure , spectroscopic experimental facilities	Dr. Nandini Garg	DAE	Government	Physical Sciences	2022	350	3 Years
Development of Schwarzschild couder Cherenkov Telescope and maintenance of existing facilities of ApSD	Dr. Kuldeep Yadav	DAE	Government	Physical Sciences	2022	260	3 Years
Development of Ne+E166+A155:A155:H166+A155:G166	Dr Pranesh Sengupta	DAE	Government	Engineering Sciences	2014	612	8 Years
Establishing Technologies and Design for Electron Accelerators	Dr(Smt)Archana Sharma	DAE	Government	Engineering Sciences	2017	500	4 Years
Experimental Studies for Ageing & Life Extension of Nuclear Components	Dr V. Kain	DAE	Government	Engineering Sciences	2014	650	7 Years
Physics of Devices and Indigenous Development of Instrumentation	Dr. A.K. Debnath	DAE	Government	Physical Sciences	2014	650	7 Years
Safety Studies Related to PHWR, AHWR and CHTR	Dr J. Chattopadhyay	DAE	Government	Engineering Sciences	2014	1074	7 Years
Sub-TeV Light Experiments(SUBTLE)	Dr K K Yadav	DAE	Government	Engineering Sciences	2005	926	16 Years
Molecular and Cellular Radiation Biology of Model Organisms and Human Population	Dr. S. Santosh Kumar	DAE	Government	Life Sciences	2015	790	6 Years
Development of Advanced Radiation Detectors and Nuclear Instrumentation	Dr. V. H. Patankar	DAE	Government	Engineering Sciences	2014	1045	7 Years
Nuclear agriculture for sustainability and societal benefits	Dr Souframanian	DAE	Government	Life Sciences	2014	343	8 Years
Synchrotron Radiation Based Physics Research	Dr D Udupa	DAE	Government	Physical sciences	2015	639	7 Years
Astrophysics and Accelerator based Research in Physical Sciences	Dr. S. Santra	DAE	Government	Physical sciences	2015	507	7 Years
Physics studies and enabling Technology development for ion accelerators	Dr KrishnaGopal S	DAE	Government	Physical Sciences	2013	1280	10 Years

Compilation of data as received from
Dean-Academic of various CI's/OCC of HBNI.


प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Pattern of care and survival studies Breast cancer	Dr. Rajesh Dikshit	NCRP, ICMR	Government	Medical & Health Sciences	2006	6.75	19 Years
Pattern of care and survival studies Head and Neck cancer	Dr. Rajesh Dikshit	NCRP, ICMR	Government	Medical & Health Sciences	2006	6.75	19 Years
Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer	Dr. Nita Nair	DAE Capital budget	Government	Medical & Health Sciences	2010	79.89	15 Years
A randomized trial comparing intensity modulated external beam radiation alone vs intensity modulated radiation and brachytherapy for reduction in xerostomia in patients with early staged oropharyngeal cancers	Dr. Ashwini Budrukkar	Department of Atomic Energy	Government	Medical & Health Sciences	2010	54.54	12 Years 8 Months 4 Days
A Double Blinded Phase III Randomized Placebo Controlled Trial to Evaluate the Efficacy of Tranexamic Acid to Reduce Operative Blood Loss in Bone Tumor Patients	Dr. Ashish Gulia	DST	Government	Medical & Health Sciences	2018	9.98	4 Years 6 Months
Prospective study to identify biomarkers of chemoresistance to neoadjuvant chemotherapy and discover targetable pathways in triple-negative breast cancer.	Dr. Nita Nair	DST	Government	Medical & Health Sciences	2018	42.85	5 Years
A phase III randomised trial of metronomic maintenance with oral methotrexate and propranolol versus observation after chemotherapy in relapsed platinum sensitive high grade epithelial ovarian cancer.	Dr. Jaya Ghosh	Indian Council of Medical Research	Government	Medical & Health Sciences	2019	136.62	5 Years
In Vitro and In Vivo Functions of Cell Surface Estrogen Receptors (csERs) in the Context of Prostate Cancer.	Dr. Mahendra Pal	DAE-BRNS	Government	Medical & Health Sciences	2019	32.36	3 Years
Deep Learning neural network based radiogenomics in predicting clinicopathological outcomes in non-small cell lung cancer	Dr. Rajiv Kumar	BIRAC-PREDIBLE HEALTH	Government	Medical and Health science	2018	6.74	5 Years
To establish a ready network of clinical trial units across the National Cancer Grid to promote multi-centric collaborative research in the field of drug and device development.	Dr. Rajendra Badwe	Biotechnology Industry Research Assistance Council (BIRAC)	Non-Government	Medical and Health science	2022	232.89	3 Years
Beyond Standard Model Physics with Neutrino and Dark Matter at Energy, Intensity and Cosmic Frontiers	Dr. Manimala Mitra	CENTRE FRANCO-INDIEN POUR LA PROMOTION DE LA RECHERCHE A VANCEE	Non-Government	Physical Sciences	2021-22	8.29	3 years
Intermediate fellowship of India Alliance DBT wellcome	Dr. Mohammed Saleem	India Alliance DBT Wellcome	Non-Government	Life Science	2021-2022	93.65	5 years
Stipend for Project Fellow	Dr. Satyaprasad Premswarup Senanayak	The Peridot Technologies	Non-Government	Physical Sciences	2021-2022	1.44	1 year
Chanakya Doctoral Fellowship	Dr. Ashok Mohapatra	I-HUB QUANTUM TECHNOLOGY FOUNDATION	Non-Government	Physical Sciences	2021-2022	3.92	4 years
Research Fund grant (R21-7309528179)	Dr. P C Ravikumar	Royal Society of Chemistry	Non-Government	Chemical Sciences	2021-2022	3.91	1 year
TIRTHA	Dr. Subhankar Mishra	Dassault Systemes Foundation	Non-Government	Mathematical Sciences	2021-2022	28.50	1.5 years
Chanakya Post-Doctoral Fellow	Dr. Sanker De	I-HUB:CHAN	Non-Government	I-HUB QTF	2022-2024	12.60	2 years
EMC3-Eirene simulations of main chamber recycling on ITER	Dr. Devendra Sharma	ITER International Fusion Energy Organization	Non-government	Physical Sciences	2021	16.75	1 year 4 months

Compilation of data as received from Dean - Academic of the var

Dr. P. C. Salvin / Prof. P. C. Salvin
 REGISTRAR
 HOMI BHABHA NATIONAL INSTITUTE
 अणुशक्ति विद्यालय परिसर, अणुशक्ति नगर, मुंबई - ४०० ०९४
 Homi Bhabha National Institute School Complex, Anushakti Nagar, Mumbai - 400 094

Feasibility study on surface activation of polystyrene using low pressure plasma	Dr. Ramkrishna Rane	Accurmax Lab Devices Private Limited	Non-government	Physical Sciences	2021	6.00	1 year
A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer (SOFT Trial)	Dr. Vani Parmar	ETOP INTERNATIONAL BREST CANCER STUDY GROUP	Non-Government	Medical and Health science	2005	40.09	18 Years
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer (TEXT Trial)	Dr. Vani Parmar	ETOP IBCSG	Non-Government	Medical and Health science	2005	27.19	18 Years
Inter laboratory comparison program for immunophenotyping by flow cytometry	Dr. Sumeet Gujral	TMC-Corporate Research fund	Non-Government	Medical and Health science	2006	14.88	25 Years 5 Months 18 Days
ALTO-EGF106708- A randomized, multi-center, open-label, phase III study of adjuvant Lapatinib, Trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer	Dr. Sudeep Gupta	NOVARTIS	Non-Government	Medical and Health science	2008	63.09	15 Years
Development of a cohort study to identify and evaluate transitions in lifestyle and risk factors in a rural population with a low cancer disease risk at baseline.	Dr. Rajesh Dikshit	World Cancer Research Fund (WCRF), Center for Global Health Research (CGHR), International Agency for Research on cancer (IARC)	Non-Government	Medical and Health science	2008	119.97	13 Years
Effectiveness and safety of 2 versus 3 doses of HPV Vaccine in preventing cervical cancer: An Indian multi-centre randomized trial	Dr. Sharmila Pimple	International Agency for Research on Cancer, World Health Organization, Lyon, France	Non-Government	Medical and Health science	2010	177.37	18 Years
Establishment of registry for Epidemiology and end result - analysis in lymphoma (REEA-L) and Establishment of lymphoma tumor tissue repository at the Tata Memorial Hospital (LTTR)	Dr. Navin Khattry	DR. REDDY'S LAB	Non-Government	Medical and Health science	2010	55.00	13 Years 9 Months 19 Days
A randomized trial to evaluate the efficacy and safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients	Dr. Kumar Prabhash	TMH + NATCO Non-Government	Non-Government	Medical and Health science	2010	15.44	12 Years
Effect of COX-2 and EGFR suppression on markers of angiogenesis and proliferation in squamous cell carcinoma of oral cavity a prospective randomized study.	Dr. Sudhir Vasudevan Nair	Intramural + SERB	Non-Government	Medical and Health science	2011	40.53	12 Years
An Open label, Randomized, Investigator Initiated Multicentric, Phase III Study of Nimotuzumab in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Locally advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)	Dr. Kumar Prabhash	BIOCON	Non-Government	Medical and Health science	2011	82.14	12 Years
Asia CML Registry (ACR): Web based registry	Dr. Navin Khattry	ASIAN GOVERNMENT RESERACH FUND	Non-Government	Medical and Health science	2011	2.77	13 Years

Compilation of data as received from Dean-Academic of the Vardhman

Dr. P. S. Mehta / Prof. B. C. Selvin
कुलसचिव / REGISTRAR

होमी भाभा राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 004

Protocol No. - D420000000 : Study Code D4200C00088- A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib	Dr. Vanita Noronha	SANOFI HEALTHCARE INDIA PRIVATE LIMITED (SHIPL)	Non-Government	Medical and Health science	2011	15.40	12 Years
Phase III Study Evaluating Efficacy and Safety of low dose Gemcitabine compared to standard dose Gemcitabine with platinum in advanced non-small cell lung cancer	Dr. Kumar Prabhash	ICON	Non-Government	Medical and Health science	2012	26.12	10 Years
Establishment of audit for collating the data of lung cancer patients receiving systemic therapy with palliative intent in India.	Dr. Vanita Noronha	ICON	Non-Government	Medical and Health science	2012	3.60	11 Years
A Randomized controlled study to evaluate the role of hydroxy-progesterone in prevention of chemotherapy induced neurotoxicity in women with breast cancer	Dr. Rajendra Badwe	ICON	Non-Government	Medical and Health science	2013	80.19	10 Years
Protocol No. EMR 062202 559- A prospective, open label, multicentric data collection registry in order to describe treatment choices in management of metastatic colorectal cancer (mCRC) patients with unresectable hepatic and / or extra hepatic disease, across treatment lines (Asian Metastatic Colorectal Cancer Registry)	Dr. Shailesh Shrikhande	Merck PVT Ltd.	Non-Government	Medical and Health science	2013	8.90	9 Years
Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India	Dr. Sudeep Gupta	BIOQUEST SOLUTIONS PVT LTD	Non-Government	Medical and Health science	2014	2.87	6 Years 7 Months
Protocol No. CABAZL06500- A phase II controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel in recurrent head and neck cancer in India	Dr. Kumar Prabhash	SANOFI	Non-Government	Medical and Health science	2015	71.75	8 Years
A collaborative, multicentre, national trial for newly diagnosed patients with acute lymphoblastic leukaemia (ICICLE-2014)	Dr. Gaurav Narula	Intramural seed & ICMR / NCG	Non-Government	Medical and Health science	2014	42.46	9 Years
Protocol No. CLDK378A2301-A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer.	Dr. Sabita Jiwnani	NOVARTIS HEALTHCARE	Non-Government	Medical and Health science	2014	39.22	7 Years 2 Months
Genomic Profiling in Thyroid Carcinoma	Dr. Anuradha Chougule	ICON	Non-Government	Medical and Health science	2015	92.44	3 Years 6 Months

Compilation of data as received from Dean, Academic of the **Dr. P. C. Selvin / Prof. P. C. Selvin** Registrar, Cell of HBNI
रजिस्ट्रार / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०००९४
 Training School Complex, Anushakti Nagar, Mumbai - 400094

Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence.	Dr. Sudeep Gupta	OncoStem Diagnostics, Bangalore	Non-Government	Medical and Health science	2014	14.66	7 Years 9 Days
A Phase III randomized clinical trial to study the radiosensitizing effect of Nelfinavir in Advanced Carcinoma of Cervix. (NELCER Trial)	Dr. Supriya Chopra	TMH+ VARIAN GRANT RESEARCH	Non-Government	Medical and Health science	2017	225.96	8 Years
Prospective observational cohort study of advanced Gall bladder cancer patients to study the impact of clinical and molecular characteristics and outcome	Dr. Vikas Ostwal	MERCK PVT LTD	Non-Government	Medical and Health science	2015	39.66	7 Years
Protocol No. RI-02-003- Reditux TM Registry to compare Effectiveness, Safety and Resource Utilization of Reditux vs. the Reference Medicinal Product to treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia in Routine Clinical Practice	Dr. Manju Sengar	DR.REDDYS LAB/Phamax Analytic Resources Pvt Ltd	Non-Government	Medical and Health science	2016	32.64	7 Years
Scalp Cooling for the prevention of chemotherapy induced alopecia in breast cancer from a tertiary care cancer center in India	Dr. Jyoti Bajpai	Access Devices	Non-Government	Medical and Health science	2016	15.00	8 Years
Metronomic Adjuvant Chemotherapy Evaluation in locally advanced oral cancers post surgery and appropriate adjuvant therapy	Dr. Pankaj Chaturvedi	TMC-Corporate Research fund	Non-Government	Medical and Health science	2016	69.06	8 Years
Image Texture Analysis in assessing tumour heterogeneity: A tool to predict, prognosticate cancers and individualize radiotherapy.	Dr. Jai Prakash Agarwal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2016	97.67	7 Years
A phase III, double blind, Placebo controlled, randomized trial assessing the effect of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumor. (Add Aspirin Study)	Dr. C. S. Pramesh	TATA TRUST	Non-Government	Medical and Health science	2016	1560.33	10 Years
Pregnancy Associated Cancer (PAC) Registry to collate data on epidemiology and treatment patterns & outcomes."	Dr. Jyoti Bajpai	Roche Pvt. Ltd	Non-Government	Medical and Health science	2017	6.16	6 Years
A prospective observational study to determine the risk of Hepatitis B viral reactivation in adolescent and adult acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) with Occult Hepatitis B Infection (OHBI).	Dr. Hasmukh Jain	TMC+ UNRESTRICTED EDUCATIONAL GRANT	Non-Government	Medical and Health science	2016	2.51	8 Years
Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in hepatocellular carcinoma (IAEA study)	Dr. Supriya Chopra	IAEA	Non-Government	Medical and Health science	2016	9.40	6 Years
Evaluation of VEGF expression of tumor cells as a potential prognostic marker in Ewing's sarcoma	Dr. Jyoti Bajpai	Roche Products India Pvt. Ltd	Non-Government	Medical and Health science	2016	62.37	7 Years

Compilation of data as received from Dean-Academic of the *MA. K. J. Somaiya Institute of Postgraduate Medical Education & Research (IPGME & R)* Dr. P. C. Desai, HBNR

Registrar
 कलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - I3Y-CR-JPBQ : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or plus Placebo and to Compare Fulvestrant plus Abemaciclib or plus Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Loco regionally Recurrent or Metastatic Breast Cancer	Dr. Jyoti Bajpai	Eli Lilly and Company India Pvt. Ltd	Non-Government	Medical and Health science	2016	116.30	6 Years
Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: prospective observational study	Dr. Sarbani Ghosh Laskar	IMRT-IGRT/ Rapidarc Inc Ltd (Madison, WI, USA)	Non-Government	Medical and Health science	2017	93.16	6 Years 6 Months
A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes	Dr. Sarbani Ghosh Laskar	IAEA	Non-Government	Medical and Health science	2017	10.53	6 Years
Satisfaction in Patients on Outpatient Radiation Therapy (SPORT study)	Dr. Tejal Gupta	TMC-Corporate Research fund	Non-Government	Medical and Health science	2017	.10	6 Years 3 Months
DHANUSH : Docetaxel as radiosensitizer in Head And Neck cancer patients, Unsuitable for cisPlatin based cHemoradiation	Dr. Vijay Patil	ICON	Non-Government	Medical and Health science	2017	59.21	12 Years
A two arm randomized open label prospective parallel design superiority Phase II multicentric clinical trial to evaluate the efficacy of a doublet second line chemotherapy versus monotherapy in advanced unresectable or metastatic gall bladder cancer progressing on first line chemotherapy (GB-SELECT)	Dr. Anant Ramaswamy	TERRY FOX	Non-Government	Medical and Health science	2017	61.70	6 Years 6 Months
Profiling the incidence of ROS1 alteration discovered in human Non Small Cell Lung Cancer	Dr. Kumar Prabhash	TMH+PFIZER PVT LTD	Non-Government	Medical and Health science	2017	27.57	3 Years
Protocol No. - 000201 : An Open-label, Single-arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® (Degarelix) in Androgen Deprivation Therapy in Indian Patients Diagnosed with Advanced Hormone-dependent Prostate Cancer.	Dr. Mahendra Pal	FERRING Non-Government CEUTICAL PVT LTD	Non-Government	Medical and Health science	2017	11.09	3 Years 8 Months
A randomized trial to compare gefitinib plus chemotherapy vs chemotherapy alone in EGFR positive and T790M mutation negative advanced Non-small cell lung cancer patients after progression on first line gefitinib.	Dr. Amit Joshi	ICON -Indian cooperative Oncology Network	Non-Government	Medical and Health science	2018	31.80	5 Years

Compilation of data as received from Dean, Academic of the various CI/ACC OF HBNI

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 (रेजिस्ट्रार / REGISTRAR)
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - GBR 200-301 : A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when Given in Combination with Paclitaxel in Patients Diagnosed with HER2 Positive Metastatic Breast Cancer	Dr. Shalaka Joshi	ALKEM LABORATORIES LTD	Non-Government	Medical and Health science	2017	57.36	5 Years 6 Months
A clinical trial to test the number of circulating tumor cells (CTCs) captured by the OncoDiscover Liquid Biopsy Technology in peripheral blood samples of Head and Neck cancer patients.	Dr. Pankaj Chaturvedi	ACTORIUS INNOVATIONS AND RESEARCH PVT LTD.	Non-Government	Medical and Health science	2017	3.40	5 Years 6 Months
Quality Assurance (QA) Program for Molecular Diagnostic testing in Solid Tumors	Dr. Omshree Shetty	NATIONAL CANCER GRID	Non-Government	Medical and Health science	2017	111.06	5 Years
"Advancing Cancer-care through CANScripT TM Enabled Personalized Treatment (ACCEPT): A non-randomized, investigator initiated, observational trial to measure predictive power of CANScripT TM for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer"	Dr. Shripad Banavali	Mitra Biotech Pvt. Ltd, Bangalore	Non-Government	Medical and Health science	2018	201.69	5 Years
Phase IIb/III, Placebo-controlled, double-blind randomized clinical trial, using Curcumin and Metformin in patients with previous history of head and neck squamous cell carcinoma, in an attempt to lower the incidence of second primary tumor	Dr. Sudhir Vasudevan Nair	NATIONAL CANCER GRID	Non-Government	Medical and Health science	2018	30.79	6 Years
CONcurrent versus SEquential Chemo-Endocrine therapy in ER positive and HER2 negative non-metastatic breast cancer (CONSEQUenCE)	Dr. Shalaka Joshi	CSR Fund from Gen. Insu. Co.	Non-Government	Medical and Health science	2018	194.40	10 Years
Protocol No. - MO29872 : A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab compared with Chemotherapy in Patients with Treatment-Naïve Advanced or Recurrent (Stage IIIB not amenable for multimodality treatment) or Metastatic(Stage IV) Non-Small Cell Lung Cancer who are deemed unsuitable for Platinum-Containing therapy	Dr. Kumar Prabhsh	Roche Products (India) Pvt. Ltd	Non-Government	Medical and Health science	2017	199.11	5 Years 4 Months

Compilation of data as received from Dean Academic of the various CE/OCC of HBNZ

P. C. Selvin
 Dr. P. C. Selvin / Prof. P. C. Selvin

कुलसचिव / REGISTRAR

होमी भाभा राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - MO39196 : A Phase III, Multicentre, randomised, double-blind, placebo controlled study of Atezolizumab (anti-PD-L1 antibody) in combination with paclitaxel compared with placebo in combination with paclitaxel for patients with previously untreated, inoperable locally advanced or metastatic Triple Negative Breast Cancer.	Dr. Sudeep Gupta	Roche Products (India) Pvt. Ltd	Non-Government	Medical and Health science	2018	130.33	4 Years
Use of PET-CT with Gallium-68 labelled prostate Specific Membrane Antigen in the Diagnosis and Follow-up of patients with Prostate Cancer	Dr. Archi Agrawal	IAEA	Non-Government	Medical and Health science	2018	13.58	4 Years 6 Months
Utility of MRI in detecting peritoneal metastases in gastric cancer patients with negative CECT abdomen	Dr. Akshay Baheti	CIPLA	Non-Government	Medical and Health science	2018	6.80	6 Years
Protocol No. - I3Y-MC-JPCF : A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (MonarchE)	Dr. Seema Gulia	Eli Lilly and Company India Pvt. Ltd.	Non-Government	Medical and Health science	2018	217.30	10 Years
Prevalence of MMR status in gallbladder cancer (GBC) treated with palliative intent and its correlation with response to chemotherapy and survival.	Dr. Vikas Ostwal	Cadila healthcare limited	Non-Government	Medical and Health science	2018	17.45	5 Years
Introduction of a novel, cost effective, multigene panel for NSCLC patients - A pilot project	Dr. Rajiv Kumar	TMH-Corporate Research fund	Non-Government	Medical and Health science	2018	206.86	5 Years
Multi-Centric Clinical Trials of Indigenous TKP 2.4: Implant and Pilot Production of TKP 2.4	Dr. Ashish Gulia	Non-ferrous Materials Technology Development Centre, Hyderabad	Non-Government	Medical and Health science	2019	427.90	5 Years
Protocol No. - WO40242 : A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-Pd-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of The Head And Neck	Dr. Kumar Prabhash	Roche Products (India)	Non-Government	Medical and Health science	2018	141.74	7 Years
Protocol No. - SII-qHPV/IN-02 : A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®)	Dr. Sharmila Pimple	Serum Institute of India Pvt. Ltd, Hadapsar, Pune (Sponsor)	Non-Government	Medical and Health science	2018	137.25	5 Years 9 Months

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

REGISTRAR

होमि बांधवा राष्ट्रीय संस्थान

HOMI BAMBHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 014

Compilation of data as received from Dean, Academic of the various departments of HBNI

Prevalence of Gallstone diseases in the regions with the high and low incidence of gallbladder cancer: current status and future perspective for gallbladder cancer prevention	Dr. Sharayu Mhatre	TMC-TMC-Corporate Research fund	Non-Government	Medical and Health science	2018	69.78	4 Years
Protocol No. - 19214 : A phase IV study to investigate the safety and efficacy of regorafenib in Indian patients with metastatic colorectal cancer (mCRC)	Dr. Vikas Ostwal	Bayer AG, D-51368 Leverkusen, Germany	Non-Government	Medical and Health science	2018	87.49	5 Years
Docetaxel or Cisplatin radiosensitizer in Head and Neck cancer patients for curative or adjuvant chemoradiation	Dr. Kumar Prabhsh	Oncology Care Associates, ICON Trust	Non-Government	Medical and Health science	2018	30.84	6 Years
Sequential Abiraterone following Docetaxel Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer	Dr. Amit Joshi	TMC-TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	1362.90	10 Years
Protocol No. - ECTS/16/002 : A multicentric open label phase II safety and efficacy study of ormeloxifene in tamoxifen resistant metastatic/recurrent breast cancer patients.	Dr. Sudeep Gupta	HLL Lifecare Limited	Non-Government	Medical and Health science	2018	49.70	4 Years
Carboplatin/paclitaxel versus cisplatin/5-fluorouracil definitive chemoradiotherapy for locoregionally advanced unresectable esophageal and gastroesophageal junction cancer.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical and Health science	2018	33.72	10 Years
Protocol No. - 0063-17 : A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.	Dr. Sudeep Gupta	Intas Non-Governmentceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India	Non-Government	Medical and Health science	2018	244.65	4 Years
A pilot evaluation of prognostic molecular and serum biomarkers of disease recurrence after chemoradiation in patients with locally advanced cervical cancer from EMBRACE study group (BIO-EMBRACE-1)	Dr. Supriya Chopra	BIOEMBRACE RESEARCH GROUP	Non-Government	Medical and Health science	2019	23.60	4 Years
Two arm, triple blinded, randomized placebo controlled, prospective, parallel design Phase II integrated phase III study to evaluate the role of Carica papaya leaf extract (CPLE) in reducing the duration of chemotherapy induced thrombocytopenia and adverse events related to thrombocytopenia	Dr. Vikas Ostwal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	41.59	4 Years 5 Months
A phase-3 randomized control trial comparing hydroxyurea and L-asparaginase for cyto-reduction in pediatric AML patients presenting with hyperleukocytosis	Dr. Shripad Banavali	SOHN FOUNDATION THROUGH GRAVIS	Non-Government	Medical and Health science	2018	23.59	4 Years

1. पा. सी. सेल्विन / Prof. P. C. Selvin

Compilation of data as received from Dean - Academic of the various colleges of HBNI

REGISTRAR
होमि पाषाण राष्ट्रीय संस्थान
RGNV BHABHA NATIONAL INSTITUTE
शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Validation of the Beta Defensin Index (BDI) as a Biomarker for Oral Cancer - India	Dr. Deepa Nair	Case Western University, cleaveland	Non-Government	Medical and Health science	2018	9.02	4 Years 6 Months
A prospective evaluation of a point of care saliva-based detection test based on soluble CD44 (OncAlert) for the presence of disease in a previously untreated oral cavity and oropharynx squamous cell carcinoma.	Dr. Sudhir Vasudevan Nair	Tata Trusts, Vigilant Biosciences	Non-Government	Medical and Health science	2018	17.06	4 Years
Protocol No. - CAC2885T2301 : A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-III A and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)	Dr. Vijay Patil	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical and Health science	2019	89.05	7 Years
A Pilot study to evaluate tracer uptake characteristics in high grade neoplastic brain lesions on Ga-68 PSMA PET/CT imaging	Dr. Ameya Puranik	TMC-Corporate Research fund	Non-Government	Medical and Health science	2018	13.81	4 Years
Human cancer pathology atlas (HCPA) & Machine learning and Artificial intelligence in Pathology (MAP)	Dr. Swapnil Rane	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	1474.33	5 Years
Early detection programme for Oral, Breast and Cervical Cancer in Sangrur district of Punjab State	Dr. Atul Budukh	Local donar has donated the funds for early detection programme	Non-Government	Medical and Health science	2019	171.29	4 Years 6 Months
A two arm randomized open label Phase II clinical trial to assess the efficacy of Gemcitabine-cisplatin or Capecitabine and Concurrent chemoradiation in Operated stage II & III GB cancer (GECCOR-GB)	Dr. Anant Ramaswamy	Zydus Non-Governmentceuticals, Dr. Reddy's Laboratories Limited	Non-Government	Medical and Health science	2019	15.72	4 Years
A study of Low Dose Bevacizumab with conventional radiotherapy OR Ultra-Low Dose Radiotherapy alone in Diffuse intrinsic Pontine Glioma. (LoBULaR-DIPG)	Dr. Rahul Krishnatry	Reliance Life Sciences Pvt Ltd + BRAIN TUMOR FUND	Non-Government	Medical and Health science	2019	15.61	3 Years
Protocol No. - 0328-17 : A single arm, multicentric, open label, efficacy and safety study of Doceaqualip (Docetaxel Lipid Suspension for Injection of Intas Non-Governmentceuticals Limited, India) based regimens in metastatic gastric adenocarcinoma patients	Dr. Vikas Ostwal	Intas Non-Governmentceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India.	Non-Government	Medical and Health science	2019	82.29	3 Years 10 Months
Hematological Cancers Consortium: HCC Leukemia Registry	Dr. Manju Sengar	HCC	Non-Government	Medical and Health science	2019	116.84	10 Years
A prospective observational cohort study to identify the utility of risk-based screening strategy for long term complications in adolescent and adult cancer survivors of leukemia and lymphoma.	Dr. Hasnmukh Jain	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	32.48	5 Years

Compilation of data as received from Dean - Academic of the **Dr. P. J. Selyin / Prof. P. J. Selyin** / REGISTRAR

HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - EGC002 : A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer	Dr. Sudeep Gupta	Eirgenix Inc.	Non-Government	Medical and Health science	2019	264.00	4 Years
Evaluating The Role Of Genetic Susceptibility For Oropharynx Cancer In Indian Origin Population: a case-control study using the candidate gene approach	Dr. Sharayu Mhatre	ASCO (American Society of Cancer Oncology)	Non-Government	Medical and Health science	2019	20.18	4 Years
Phase III trial of Observation versus Irradiation for a gross totally resected grade II Meningioma	Dr. Tejpal Gupta	NRG Oncology/RTOG	Non-Government	Medical and Health science	2019	13.15	12 Years
Collaborative Action for Control of Cancer and Other Non-Communicable Diseases among Mumbai Police	Dr. Gauravi Mishra	Tata Trusts	Non-Government	Medical and Health science	2019	740.21	4 Years
Prevalence of Human Papilloma Virus in Spouses of Men diagnosed with Oral and Oropharyngeal Cancer	Dr. Gauravi Mishra	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	36.95	6 Years
COMPARISON OF TREATMENT ADHERENCE AND TOXICITIES OF HIV POSITIVE PATIENTS VS. HIV NEGATIVE CERVICAL CANCER PATIENTS IN INDIA	Dr. Lavanya Naidu	CRDF Global-ICMR	Non-Government	Medical and Health science	2019	83.03	3 Years
Health expenditure on breast cancer treatment in women: a study from public sector tertiary cancer centre [EXPERT].	Dr. Tabassum Wadasadawala	WCI-NAG foundation	Non-Government	Medical and Health science	2019	10.00	4 Years
Protocol No. - D933GCC00001 : A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)	Dr. Vikas Ostwal	Astra Zeneca Non-Government India Ltd.	Non-Government	Medical and Health science	2019	57.70	4 Years
Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer	Dr. Vedang Murthy	NRG Oncology	Non-Government	Medical and Health science	2019	84.73	6 Years
Protocol No. - CLEE011A3201C : A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical and Health science	2020	451.02	5 Years

Compilation of data as received from Dean-Academic of the various CI/OCC of HBNI

Dr. P. C. Selvin / Prof. P. C. Selvin
 कुसविब / REGISTRAR

होमी भाभा राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

A Phase II Randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic non small cell lung cancer patients-TARGET-1	Dr. Anil Tibdewal	DHR	Non-Government	Medical and Health science	2019	56.36	6 Years
A prospective observational study to compare speech and swallowing outcomes in patients undergoing treatment for oral tongue cancers	Dr. Shiva Kumar Thiagarajan	ICON	Non-Government	Medical and Health science	2019	10.00	3 Years
Protocol No. - LUF-44-001 : Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Suyash Kulkarni	Guerbet	Non-Government	Medical and Health science	2020	1.81	1 Years
Trastuzumab in HER2 positive Advanced Biliary tract cancers - single arm prospective phase II clinical trial (TAB trial)	Dr. Vikas Ostwal	Dr reddy' s LTD	Non-Government	Medical and Health science	2019	453.82	5 Years
Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study	Dr. Bhausahab Bagal	Amgen Inc	Non-Government	Medical and Health science	2019	122.98	4 Years 11 Months
Protocol No. - E7080-M091-507 : Prospective Single Arm Post Marketing Phase IV study to assess the Safety and Efficacy of Lenvatinib in Subjects with Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer	Dr. Vijay Patil	Eisai Non-Governmentceuticals India Pvt. Ltd.	Non-Government	Medical and Health science	2019	30.19	3 Years 1 Months
A study of HCC correlating its biology with Clinico demographic and ethnic features along with its Survival outcomes	Dr. Vikas Ostwal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	20.83	3 Years
A Prospective Observational Study of longitudinal assessment of neurocognitive function in patients with 1-4 brain metastases of NSCLC treated with Cranial Irradiation	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	14.04	4 Years
A New Method for Cervical Cancer Screening in Low- and Middle-Income Countries (LMIC): Training and Technical Validation of Automated Visual Evaluation (AVE) in India	Dr. Rajesh Dikshit	Clinton Health Access Initiative (CHAI), USA	Non-Government	Medical and Health science	2019	939.16	2 Years
HEmodynamic Resuscitation and Monitoring in Early Sepsis (HERMES Study)	Dr. Sheila Myatra	ISCCM	Non-Government	Medical and Health science	2019	1.00	2 Years 6 Months
Protocol No. - ALK18/ENZ124-CET1 : A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).	Dr. Kumar Prabhash	ALKEM LABORATORIES LIMITED	Non-Government	Medical and Health science	2019	146.84	

डॉ. पी. सी. सेल्विन / Prof. P. C. Selvin

कुलसचिव / REGISTRAR

होमी प्रभास राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
शिक्षण विद्यालय परिसर, अणुशास्त्री नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean-Academic of the various schools of HBNI

Protocol No. - QB46C-H03 : Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Tumours	Dr. Gouri Pantvaitya	QBiotics Group Limited (QBiotics)	Non-Government	Medical and Health science	2019	70.66	4 Years
Protocol No. - CLEE011A2207 : A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical and Health science	2019	88.30	3 Years
Comparative performance evaluation of Artificial Intelligence (AI) based visual inspection test (AI_VIA) with Primary Health Worker administered VIA (PHW_VIA), HPV DNA test and cervical cytology to detect cervical pre-cancer lesions.	Dr. Sharmila Pimple	Periwinkle Technologies Pvt. Ltd., Pune	Non-Government	Medical and Health science	2019	6.68	3 Years
Protocol No. - NIS/2018/19 : An open label, single arm, multicentric, observational study to evaluate safety and effectiveness of Akynzeo®, an oral fixed dose combination of netupitant and palonosetron in the management of CINV, in the real world settings of India	Dr. Sudeep Gupta	Glenmark Non-Governmentceuticals Ltd.	Non-Government	Medical and Health science	2020	10.41	2 Years 6 Months
Carboplatin / Paclitaxel Versus Cisplatin/ Etoposide as Definitive Chemoradiotherapy for LocoRegionally advanced Non small Lung cancer (NSCLC): A Phase III Randomized Controlled Trial	Dr. Ajaykumar Singh	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	33.72	11 Years
Phase 3 non inferiority randomised study between low dose immunotherapy and cytotoxic chemotherapy in 2nd line or beyond setting in relapsed-recurrent or metastatic solid tumors	Dr. Rajendra Badwe	Trilokchand Papiwal Charitable Trust	Non-Government	Medical and Health science	2020	331.29	5 Years
A phase III randomized controlled trial of two radiotherapy fractionation regimens in metastatic epidural spinal cord compression in lung cancer patients	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	29.54	6 Years
Protocol No. - MK3475-593-03 : A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) in India (Keynote-593)	Dr. Jyoti Bajpai	MSD Non-Governmentceuticals Pvt Ltd	Non-Government	Medical and Health science	2020	456.11	5 Years

Compilation of data as received from Dean-Academic of the Vardha Institute of Postgraduate Medical Education and Research (VIMR) of HBNI

डॉ. पी. सी. सेल्विन / Prof. P. C. Selvin
 निदेशक/REGISTRAR

होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer-CompARE trial	Dr. Devendra Chaukar	University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT	Non-Government	Medical and Health science	2020	58.86	6 Years
A pilot study to determine the feasibility of detection of esophageal cancer by sponge cytology technique.	Dr. Sabita Jiwnani	Dr. Virginia R. Little, Boston University, Collamore 7, Suite7380	Non-Government	Medical and Health science	2020	.08	2 Years 6 Months
An open label, prospective three-arm randomized, non-comparative study on efficacy and tolerability of orally disintegrating strip, oral tablets and intravenous administration of Vitamin B12, in post-gastrectomy Indian patients	Dr. Sujay Srinivas	EISAI Non-Government pharmaceuticals	Non-Government	Medical and Health science	2020	38.34	6 Years
Protocol No. - DRL-INDG02-PAN/2018 : An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize its Safety, Tolerability and Activity in Indian Subjects with Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer	Dr. Vikas Ostwal	Dr. Reddy's Laboratories Ltd.	Non-Government	Medical and Health science	2020	26.89	3 Years
Adjuvant chemotherapy for operated amPullary AdenoCarcinomas based on Histology and Intensification ; A two arm non - randomized open label prospective parallel adaptive design phase II clinical trial (APACHI)	Dr. Anant Ramaswamy	Educational Grant - Reliance Life Science / DAECTC	Non-Government	Medical and Health science	2020	11.20	7 Years
A randomized study to evaluate the effectiveness of Gabapentin on Oral-Mucositis induced pain due to chemo-radio therapy in patients with head and neck cancers.	Dr. Nandini Menon	CADILA	Non-Government	Medical and Health science	2020	21.22	3 Years
A phase II study to evaluate the role of short-course Pomalidomide in maintaining treatment-free remission post tyrosine-kinase inhibitor (TKI) discontinuation in adult patients with chronic myeloid leukemia-chronic phase (CML-CP).	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	84.00	6 Years 6 Months
Epithelial-mesenchymal transition (EMT) and Breast Cancer Stemness: Defining the role of OVOL and ACTN4 in cross talk	Dr. Omshree Shetty	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	26.14	2 Years
Grid Oncology: Remaking Cancer Care in India	Dr. C. S. Pramesh	Wellcome Trust	Non-Government	Medical and Health science	2020	30.36	3 Years
An open label, randomized, clinical trial of Mycobacterium w (Mw) as an Adjuvant to chemotherapy in Advanced Non-small Cell Lung Cancer	Dr. Kumar Prabhash	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	194.61	4 Years
Standard Maintenance Therapy versus Local Consolidation Radiation Therapy and Standard Maintenance Therapy In 1-5 sites of oligometastatic Non-Small Cell Lung Cancer (NSCLC) - A Phase III Randomized Controlled Trial (TARGET-2)	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	60.80	6 Years

Compilation of data as received from Dean-Academic of the various universities / REGISTRAR of HBN I

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

A Prospective Observational Study on Outcomes of Bone Metastases treated with Radiotherapy in Lung Cancer	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	17.80	3 Years
Indian Pulmonary Embolism Registry (IndiPER)	Dr. Sohan Solanki	ETERNAL HOSPITAL JAIPUR	Non-Government	Medical and Health science	2020	.15	3 Years
A randomized, open label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with standard triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy induced Nausea and vomiting in subjects with osteosarcoma and other solid tumors (OLAnzaPINE)	Dr. Jyoti Bajpai	PROGRESSIVE LADIES WELFARE SOCIETY (NGO)	Non-Government	Medical and Health science	2020	5.29	2 Years
Phase I study to evaluate the feasibility and safety of addition of ruxolitinib to a standard BFM-90 regimen in adolescent/adult Ph-like ALL.	Dr. Hasmukh Jain	EM- LADY TATA MEMORIAL TRUST	Non-Government	Medical and Health science	2020	74.98	4 Years
Focal Radiotherapy Plus Low-Dose Craniospinal Irradiation Followed By Adjuvant Chemotherapy In WNT Subgroup Medulloblastoma (FOR-WNT 2 Study)	Dr. Tejal Gupta	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	37.50	10 Years
Observation or upfront cranial RT in oncogene driver mutated NSCLC with asymptomatic brain metastases: A phase III Randomized Controlled Trial	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	85.60	6 Years
A prospective study to design therapeutic drug monitoring strategy for dasatinib in CML patients	Dr. Manjunath Nookala	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	34.09	3 Years
Protocol No. - D0816R00025 : A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study)	Dr. Sudeep Gupta	Astra Zeneca Non-Government India Limited	Non-Government	Medical and Health science	2020	147.67	3 Years
Protocol No. - TX05-03E : A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03	Dr. Sushmita Rath	Tanvex Biologics Corp.	Non-Government	Medical and Health science	2020	116.24	2 Years
Protocol No. - D3614C00001 : A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC).	Dr. Sudeep Gupta	Astra Zeneca Non-Government India Limited	Non-Government	Medical and Health science	2020	545.53	2 Years 4 Months
Seroprevalence of COVID-19 in slum and non slum areas of Mumbai	Dr. Rajesh Dikshit	i-spirit	Non-Government	Medical and Health science	2020	261.01	3 Months

पो. पा. सी. सेल्विन / Prof. P. C. Selvin
REGISTRAR

Compilation of data as received from Dean-Academic of the various colleges of HBNI

HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

A phase II randomized study to evaluate the efficacy of short-course RR CVEP regimen against short course EPOCH-RR in adolescent and adult seropositive Diffuse large B cell lymphoma	Dr. Manju Sengar	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	139.65	3 Years
A pilot study of indigenously manufactured HCAR19 (2nd generation Anti-CD19-41BBDD3 (zeta) chimeric antigen receptor T-cell therapy) in adult patients with relapsed/refractory diffuse large B-cell lymphoma.	Dr. Hasmukh Jain	Immunoadoptive cell therapy private limited,	Non-Government	Medical and Health science	2020	75.54	10 Years
Angiotensin receptor blockade with losartan plus mFOLFIRINOX versus mFOLFIRINOX alone in advanced Pancreatic AdenoCarcinomas - a two arm open label prospective Phase III parallel design randomized superiority clinical trial (AFPAC)	Dr. Anant Ramaswamy	EM - LUPIN PVT LTD	Non-Government	Medical and Health science	2021	33.92	7 Years
Protocol No. - D933AC00001 : A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)	Dr. Vikas Ostwal	Astra Zeneca	Non-Government	Medical and Health science	2020	118.59	2 Years
A prospective, multicentre, post-marketing phase IV study to assess the safety and efficacy of Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC)	Dr. Vikas Ostwal	Eisai Non-Governmentceuticals, India Pvt. Ltd, 6th Floor, A Wing, Marwah Center, Krishanlal Marwah Marg, Andheri East, Mumbai 400072, Maharashtra, INDIA, Phon	Non-Government	Medical and Health science	2021	9.40	2 Years
AN OBSERVATIONAL STUDY TO DETERMINE THE ACCURACY OF OXYGEN RESERVE INDEX (ORI) TO PREDICT IMPENDING DESATURATION IN PATIENT'S UNDERGOING PROCEDURES UNDER APNOEA	Dr. Jeson Doctor	Smt KMD Medical Charitable Trust	Non-Government	Medical and Health science	2020	1.30	2 Years
Influence of Preoperative Vitamin-D, Serum Magnesium and Serum Phosphate levels on the development of transient and permanent hypocalcaemia and hypoparathyroidism following total thyroidectomy with or without central compartment clearance in patients with thyroid cancer (HypoCal Study).	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	18.33	4 Years
Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial	Dr. Jigeeshu Divatia	The George Institute for Global Health Plot No. 57, Second Floor, Corporation Bank Building Nagarjuna Circle, Punjagutta, Hyderabad - 500 082, Telanga	Non-Government	Medical and Health science	2020	6.00	2 Years

Compilation of data as received from Dean-Academic of the ~~various~~ ^{various} Cl/oc of HBNZ

प्रा. प्रो. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
(पु.सो.) भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Prophylactic pifrenidone for prevention of radiation induced pneumonitis in patients with Lung cancer (PROPER study)	Dr. Naveen Mummudi	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	1.00	2 Years
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).	Dr. Vikas Ostwal	Astra Zeneca	Non-Government	Medical and Health science	2021	66.57	3 Years
COVID-19 with Hematological Cancers Registry of India (CHCRI)	Dr. Lingaraj Nayak	Hematology Cancer Consortium (HCC)	Non-Government	Medical and Health science	2021	1.08	1 Years 6 Months
Evaluating Immunohistochemical and Molecular Landscape of Select Osteoclastic Giant Cell Rich Tumors of the Bone	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	12.38	2 Years
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02).	Dr. Vikas Ostwal	Astra Zeneca	Non-Government	Medical and Health science	2021	18.71	3 Years
Evaluation of the effect of foot bathing on peripheral neuropathy in patients receiving oxaliplatin containing chemotherapy for GI cancer at Tata Memorial Hospital	Mrs. Anita D Souza	IASCC	Non-Government	Medical and Health science	2021	2.41	3 Years
Early T-cell precursor acute lymphoblastic leukaemia: Unravelling mechanisms of resistance and development of novel therapeutic strategies	Dr. Manju Sengar	Lady Tata Memorial Trust	Non-Government	Medical and Health science	2021	197.82	4 Years
Protocol No. - D967JC00001 : A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)	Dr. Sudeep Gupta	Astra Zeneca	Non-Government	Medical and Health science	2021	144.14	3 Years
Avoiding prophylactic growth factors during paclitaxel phase of dose dense adjuvant chemotherapy in breast cancer	Dr. Seema Gulia	Indian Association of Supportive Care	Non-Government	Medical and Health science	2021	3.00	2 Years
Obesity and non-communicable disease in India: an imaging study of 10,000 adults in the Indian Study of Healthy Ageing (ISHA cohort study).	Dr. Sharayu Mhatre	CTSU UK, UNIVERSITY OF OXFORD	Non-Government	Medical and Health science	2021	190.24	3 Years
Pilot study for measurement of intra-tumoral interstitial fluid pressure in various cancers	Dr. Qurratulain Ali Chougale	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	53.76	2 Years
Prevalence, predisposing factors and management of Head and Neck Lymphedema in patients following treatment for Head and Neck Cancer. (HeNLY-1 Study)	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	8.22	4 Years

डॉ. पी. सी. सेल्विन / Prof. P. C. Selvin

कुलसचिव / REGISTRAR

होमि भाभा राष्ट्रीय संस्थान of HBNI

HOMI BHABHA NATIONAL INSTITUTE

शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४

Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean - Academic of the various schools of HBNI

Protocol No. - D9311C00001 : A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)	Dr. Sudeep Gupta	Astra Zeneca	Non-Government	Medical and Health science	2021	200.86	4 Years
An open label phase III randomized clinical trial of pomalidomide cyclophosphamide and dexamethasone versus pomalidomide dexamethasone in relapsed/ refractory multiple myeloma treated with lenalidomide and a proteasome inhibitor.	Dr. Lingaraj Nayak	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	19.30	3 Years 10 Months
A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)	Dr. C. S. Pramesh	Astra Zeneca	Non-Government	Medical and Health science	2021	63.56	7 Years 6 Months
The Clinical Value of Ultrasound based Navigation update in cranial resection procedures	Dr. Aliasgar Moiyadi	Brainlab AG	Non-Government	Medical and Health science	2021	33.25	2 Years
A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors (NAVIGATE)	Dr. Vikas Ostwal	Non-US: Bayer Consumer Care AG, Peter-Merian-Strasse 84, 4052 Basel, Switzerland US-territory: Bayer HealthCare Non-Governmentceuticals Inc., 100 Bayer Boule	Non-Government	Medical and Health science	2021	51.25	3 Years
A randomized phase III clinical trial evaluating the non-inferiority of reduced dose chemotherapeutic regimens based on CARG risk scores compared to standard doses in Older patients with advanced esophageal, esophagogastric, gastric, and biliary tract cancers (CARGO study)	Dr. Anant Ramaswamy	TMC-Corporate Research fund	Non-Government	Medical and Health science	2022	60.10	6 Years
Preventing Cervical Cancer in India through self-sampling (PCCIS)	Dr. Gauravi Mishra	Fund for Innovation and Transformation, program of the Inter-Council Network of Provincial and Regional Councils (ICN), Global Affairs Canada.	Non-Government	Medical and Health science	2021	65.95	1 Years 3 Months
Protocol No. - D8220C00022 : A prospective, multi-centre, phase IV clinical trial to assess the safety and efficacy of Acabrutinib capsules in Indian adult patients with chronic lymphocytic leukemia and relapsed and refractory mantle cell lymphoma	Dr. Manju Sengar	Astra Zeneca	Non-Government	Medical and Health science	2021	29.45	2 Years

Compilation of data as received from Dean, Academic of the

Dr. P. C. Selvin / Prof. P. C. Selvin
 REGISTRAR OF HBNI
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Impact of on-demand training & audio-visual aids to improve referral rates for genetic counselling and/ testing at a tertiary cancer centre (Mainstreaming Study)	Dr. Rima Pathak	Astra Zeneca	Non-Government	Medical and Health science	2022	10.00	2 Years
A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients with Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer	Dr. Vijay Patil	Astra Zeneca	Non-Government	Medical and Health science	2022	3.00	1 Years
Psychological distress in adolescents and young adults (AYA) with cancer referred to Psycho-oncology service: a single centre prospective observational study in a low middle income country setting	Dr. Jayita Deodhar	TMC-Corporate Research fund	Non-Government	Medical and Health science	2022	12.82	2 Years
Immunohistochemical analysis of LLT1 on prostate cancer biopsy samples	Dr. Santosh Menon	Zumutor Biologics	Non-Government	Medical and Health science	2021	4.58	1 Years
Women Empowerment-Cancer Awareness Nexus (WE-CAN): An Implementation Research Study of Cervical Cancer Prevention through HPV Self-Sampling and Education in India	Dr. Gauravi Mishra	Indian Medical Council of Research (ICMR) & Canadian Institutes of Health Research (CIHR) under Global Alliances for Chronic Diseases(GACD)	Non-Government	Medical and Health science	2021	1571.48	5 Years
A randomized, double-blind, placebo-controlled Phase 3 study of Darolutamide in addition to androgen deprivation therapy (ADT) versus placebo ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).	Dr. Amit Joshi	Covance India Non-Governmentceutical Services Pvt. Ltd.	Non-Government	Medical and Health science	2021	439.17	3 Years
An Open-label, Multicenter, Randomized Phase 3 Study of First line Encorafenib Plus Cetuximab With or Without Chemotherapy versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus Chemotherapy in Participants with Metastatic BRAF V600E Mutant Colorectal Cancer	Dr. Vikas Ostwal	PFIZER	Non-Government	Medical and Health science	2021	60.88	3 Years
Protocol No. - WO42633 : A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY (ASTEFANIA STUDY).	Dr. Sudeep Gupta	Roche Products (India) Pvt. Ltd.	Non-Government	Medical and Health science	2022	505.21	10 Years

Compilation of data as received from Dean, Academic of the Homi Bhabha National Institute

प्रा. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - DP-1111-02CT : A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)	Dr. Venkatesh Rangarajan	ITM Solucin GmbH	Non-Government	Medical and Health science	2022	94.45	10 Months 1 Days
REal-World tTreatment outcomes for Asian breast cancer paTIEnt (REWRITE Study)	Dr. Seema Gulia	Novartis Oncology Novartis (Thailand) Limited	Non-Government	Medical and Health science	2022	14.66	1 Years
Developing precision immunotherapy for value-based treatment of lung cancer in India	Dr. C. S. Pramesh	DBT/Wellcome Trust india Alliance	Non-Government	Medical and Health science	2021	999.10	5 Years
Protocol No. - GO42784 : A Phase III, Randomized, Open Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer	Dr. Sudeep Gupta	Hoffmann-La Roche Ltd	Non-Government	Medical and Health science	2022	520.90	10 Years
PErioperative respiratory care and outcomes for patieNts Undergoing high risk abdomiNal surgery	Dr. Sohan Solanki	University of Birmingham	Non-Government	Medical and Health science	2022	1.80	2 Years
Protocol No. - D0817R00044 : A non-interventional, multicenter study to determine the prevalence of homologous recombination repair (HRR) gene mutation in patients with metastatic castration-resistant prostate cancer in India	Dr. Nandini Menon	Astra Zeneca	Non-Government	Medical and Health science	2022	11.25	1 Years 6 Months
A Multi-country, Multi-centre, Non-interventional, REtrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant PROstate Cancer.	Dr. Amit Joshi	Astra Zeneca	Non-Government	Medical and Health science	2022	8.65	1 Years
Evaluation of Adequacy of Pain Relief and Medications Used in Pain Management in Cancer Patients Attending Palliative Medicine Out-Patient Department in a Tertiary Care Hospital	Dr. Raghu Thota	Research Society KEM Hospital	Non-Government	Medical and Health science	2022	.07	1 Years
National Postdoctoral Fellowship	Dr. Antarjami Sahoo (NPDP) under mentorship of Dr. Subhankar Bedanta	Jawaharlal Nehru Centre for Advanced Scientific Research	Non-Government	Chemical Sciences	2021-2022	6.46	2 years
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel versus Weekly Paclitaxel Plus Weekly Carboplatin in Women with Triple Negative Breast Cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2009	65.40	

डॉ. पी. सी. सेल्विन / Prof. P. C. Selvin

कलसंबंध / REGISTRAR

13 Years

होमि भबहा नेशनल इंस्टीट्यूट
HOMI BHABHA NATIONAL INSTITUTE

शिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean - Academic of the various Institutes of HBNI

Image Guided Radiation Therapy (IGRT) in Cervical Cancers	Dr. Umesh Mahantshetty	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2011	20.16	10 Years 1 Months 6 Days
Randomized controlled trial to assess blockade of voltage gated sodium channels during surgery in operable breast cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2011	73.06	13 Years
Prevalence of malnutrition in patients with lung cancer	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	10.53	5 Years
Prospective Phase III randomized trial of prostate only or whole pelvic radiotherapy in high risk prostate cancer (POP-RT trial)	Dr. Vedang Murthy	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2011	19.92	11 Years
Phase III non-inferiority randomized trial comparing three-weekly Cisplatin versus weekly Cisplatin in combination with radiation therapy in patients with advanced carcinoma of the head and neck	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2012	45.93	11 Years
A Phase III Double Blind Randomized Placebo Controlled study of Trastuzumab as Short Duration Preoperative Therapy in patients with HER2-neu Positive Operable Breast Cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2012	52.63	11 Years
Randomised controlled trial assessing addition of neoadjuvant and maintenance oral metronomic chemotherapy to standard surgery and adjuvant therapy in Stage III/IV Operable Oral cancers	Dr. Prathamesh Pai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2012	79.74	11 Years
Phase II Randomised Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers	Dr. Gouri Pantvaidya	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2012	22.17	14 Years
Demographic profile of lung cancer and its treatment in India	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2012	2.96	10 Years
Comparative study for efficacy and safety of Paclitaxel with Cisplatin/Carboplatin versus 5-Fluorouracil with Cisplatin/Carboplatin in resectable carcinoma esophagus or gastroesophageal junction carcinoma	Dr. Kumar Prabhash	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2013	3.78	9 Years 10 Months
Prospective Screening log for patients with recurrent or second primary Head and Neck Cancers referred for re-Radiotherapy.	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2014	6.40	9 Years
Ophthalmic Outcomes After Treatment of Paranasal sinus Tumors	Dr. Devendra Chaukar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2013	.35	8 Years 3 Months 22 Days
Observational study to evaluate the outcome of prescreen failure and screen failure patients who receive chemoradiation for locally advanced Head and Neck Cancer	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2014	8.64	9 Years
Pilot study to assess the presence of hypoxia related biomarkers in patients with oral cancer	Dr. Gouri Pantvaidya	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2014	53.85	9 Years
A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinoma	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2014	1.92	9 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR

Compilation of data as received from Dean-Academic of the various HBNZ HOMI BHABHANATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Germ Cell tumor outcome and long term follow up study (GTOF)	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2014	5.04	8 Years
Prevalence and predictors of malnutrition and its impact on quality of life in patients with Gastric cancer - a single centre prospective study	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2014	21.00	8 Years
Prospective non-randomized study to compare accuracy of clinical examination under anesthesia, axillary ultrasound and histo-pathological examination for axillary nodal staging in women with clinically NO early breast cancer.	Dr. Vani Parmar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	3.75	8 Years
Feasibility and implications of thoracoscopic dissection of internal mammary nodes in central and inner quadrant breast cancer	Dr. Sabita Jiwnani	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	35.27	8 Years
Utility of pectoralis major myofascial flap in reducing pharyngocutaneous fistula rates after salvage total laryngectomy.	Dr. Devendra Chaukar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	28.41	9 Years
Phase III randomized trial of high dose chemoradiation and systemic chemotherapy vs systemic chemotherapy alone in patients with unresectable nonmetastatic cholangiocarcinoma	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	105.61	8 Years
Comparison of incidence of precursor and pre-invasive lesions of the gall bladder in patients operated for chronic cholecystitis and cholelithiasis in endemic and non-endemic regions in India.	Dr. Mukta Ramadwar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	56.77	7 Years
Prospective Pilot Study: Oncologic safety and Functional outcome following Neo-adjuvant Chemotherapy in T2-T4a Tongue cancers	Dr. Prathamesh Pai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	39.06	6 Years
Survivorship programme for colorectal cancers patients- a randomized study	Dr. Avanish Saklani	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	25.00	10 Years
Role of electrochemotherapy for head and neck and breast cancers in a palliative setting	Dr. Devendra Chaukar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	2.03	6 Years 7 Months 20 Days
Study of quality of life of CA Ovary patients from a tertiary care cancer centre	Dr. Jyoti Bajpai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	4.51	7 Years
Conventional Radiography based Intracavitary Brachytherapy (Standard Arm) versus Magnetic Resonance Image based BrAchyTherapy (Study Arm) in Locally Advanced Cervical Cancers: A Phase III Randomized Controlled Trial (COMBAT - Cervix Trial)	Dr. Lavanya Naidu	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	146.40	7 Years
NIS expression detection in metastatic breast cancer with 131I NaI	Dr. Venkatesh Rangarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	3.00	5 Years 3 Months

पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 हीमा भाभा राष्ट्रीय संस्थान
 HBNZ BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean - Academic of the various colleges of HBNZ

A prospective study to evaluate the feasibility of hippocampal sparing intensity modulated radiotherapy in preserving neurocognitive functions in adult patients with pituitary adenoma.	Dr. Jayant Goda	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	4.45	7 Years
Perioperative therapy (preop chemo v/s CTRT) in locally advanced gall bladder cancers (POLCA-GB)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	70.28	7 Years
Performance of HPV DNA Test in presence of co-infection with common RTIs	Dr. Sharmila Pimple	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	6.69	6 Years 6 Months
Randomized trial of effect of two fractionation schedules of Adjuvant Radiation following Immediate Autologous Breast Reconstruction (ARIA-BR) on Toxicity and Patient Reported Outcome Measures.	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	40.85	8 Years
Audit of clinical outcomes of adjuvant whole breast or chest wall with or without regional irradiation in women of breast cancer treated with different fractionation schedules over two years.	Dr. Ashwini Budrukkar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	3.60	6 Years
Acceptability and validity of self sampling for high risk HPV detection among women in Maharashtra	Dr. Gauravi Mishra	PHFI THROUGH THE PH LEADER PRPGRAMME	Non-Government	Medical & Health Sciences	2017	75.62	6 Years 2 Months
Efficacy and tolerability of two different bowel preparation regimens for pre-colonoscopy bowel cleansing in treatment naive Indian patients with colorectal cancer; a single center prospective randomized single blind study	Dr. Shaesta Mehta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.74	3 Years
Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST) -a prospective randomized control trial	Dr. Sudhir Vasudevan Nair	National Cancer Grid	Non-Government	Medical & Health Sciences	2016	418.37	7 Years
Study of the Nephron Sparing Surgeries done at Tata Memorial Hospital	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	.40	8 Years
Protocol No. - NA : Image guided intensity modulated External beam Radiotherapy and MRI based adaptive Brachytherapy in Locally advanced Cervical Cancer. EMBRACE-II	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	48.25	9 Years
Efficacy of Bortezomib and Rituximab in newly diagnosed adolescent and adult CD20 positive Philadelphia (Ph) negative Precursor B-cell acute lymphoblastic leukemia: Phase II study	Dr. Manju Sengar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	82.94	6 Years
Histopathologic and Immunohistochemical Features of Solitary Fibrous Tumors of Soft Tissues	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.72	4 Years 1 Months
Clinicohistopathological correlation of esthesioneuroblastoma and assessment of prognostic impact of expression of apoptosis markers cleaved Caspase 3, XIAP, Survivin and proliferative marker Ki-67	Dr. Asawari Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.87	

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

कुलसचिव / REGISTRAR

होमिभाषा राष्ट्रीय संस्थान

HOMI BHASHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean-Academic of the various CAs/PGCs of HBNI

A Feasibility and Safety Study of Single Application Multifractionated High Dose Rate Brachytherapy in Locally Advanced Cervical Cancer	Dr. Lavanya Naidu	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	26.06	4 Years
A prospective COhort study of breast cancer patients with New bone metastases to estimate Quality of life, health Economics & Risk of skeletal complications (CONQUER)	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	27.70	6 Years
A comparison of clinicopathological profile of non-B non C hepatocellular cancer (HCC) and Hepatitis B or C related HCC	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	.18	6 Years
Effect of Pre Operative Distress Levels on Post Surgical Wound Healing in Head Neck Squamous Cell Carcinoma Patients	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	3.23	4 Years 6 Months
Clinicopathologic Features of Undifferentiated Round Cell Sarcomas of Bone and Soft Tissues	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	8.08	5 Years 6 Months
A randomized controlled trial to evaluate the safety of breast conserving surgery post neo-adjuvant therapy locally advanced breast cancer.	Dr. Nita Nair	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	12.07	12 Years
A cross-sectional feasibility study of a telephonic questionnaire by research nurses for follow-up of locally advanced cervical cancer patients with complete response to treatment	Dr. Lavanya G	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	3.84	5 Years
Evaluating the clinical utility of new immunophenotypic markers in the determination of minimal residual disease in childhood acute myeloid leukemia.	Dr. Prashant Tembhare	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	4.03	5 Years
Pilot study to evaluate the biodistribution & dosimetry of 177Lu - Trastuzumab in HER2 receptor positive metastatic breast carcinoma and its toxicity & efficacy profile	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	122.99	5 Years
Esophagectomy Complications Platform and Quality Measures: What is the Contemporary Incidence of Complications at High Volume Esophagectomy Centers?	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	23.57	10 Years
Utility of MRI in evaluation of pancreatic cancer for predicting and assessing response to neoadjuvant chemotherapy: A prospective observational study	Dr. Akshay Baheti	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	4.15	5 Years
Acupuncture as a modality of treatment for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer-A Phase 3 Randomized Controlled Trial (ABC-CIPN).	Dr. Jyoti Bajpai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	4.72	5 Years
Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children with Acute Lymphoblastic Leukemia: A Pilot Study	Dr. Maya Prasad	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	61.22	

T. पी. सी. सेल्विन / Prof. P. C. Selvin

कुलसचिव / REGISTRAR
 डॉ. पी. भाभा राष्ट्रीय संस्थान
 P. M. BHABHA NATIONAL INSTITUTE
 आरक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Annex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean - Academic of the various College of HBNI

Prevalence and predictors of malnutrition and its impact on quality of life and prognosis in patients with hepatobiliary tumors - a prospective study	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	20.79	5 Years
Prevalence and predictors of malnutrition and its impact on quality of life and prognosis in patients with pancreatic tumours - a prospective study	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	29.16	5 Years
A randomized clinical trial evaluating the efficacy and safety of the addition of postoperative chemoradiation versus observation in patients with high-risk esophageal squamous cell carcinoma following surgery	Dr. Devayani Niyogi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	300.32	12 Years
Establishment of national gall bladder cancer registry	Dr. Mahesh Goel	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	18.77	6 Years
A Phase 2 randomized controlled trial to evaluate the role of modified C.O.M.B.A.T maintenance regimen in children with high risk medulloblastoma	Dr. Girish Chinnaswamy	Terry Fox Foundation	Non-Government	Medical & Health Sciences	2018	58.42	4 Years
Precision medicine and Malnutrition- A Model based approach to dose chemotherapy in pediatric patients with malnutrition	Dr. Girish Chinnaswamy	Terry Fox Foundation	Non-Government	Medical & Health Sciences	2018	172.91	5 Years
A randomized phase 2/3 trial of Rosuvastatin with neo-adjuvant chemo-radiation in patients with rectal cancer	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	124.20	7 Years
Effect Of Pre-Operative Transarterial Embolisation On Circulating Tumor Cells And Recurrence In Hepatocellular Carcinoma	Dr. Mahesh Goel	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	13.70	4 Years
A Double Blind Randomized Controlled Trial of Renal Protective Effects of Normal Saline Plus Placebo Versus Normal Saline Plus Mannitol Prior to Cisplatin Containing Chemotherapy Regimens in Osteosarcoma and other Solid Tumors.	Dr. Jyoti Bajpai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	34.41	4 Years
Revisiting grading of squamous carcinoma using computational methods	Dr. Swapnil Rane	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	11.75	5 Years
Feasibility Of Magnetic Resonance Image Based Target Delineation In Radical High Dose Rate Interstitial Brachytherapy For Early Oral Cavity Cancers: A Pilot Study	Dr. Ashwini Budrukkar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	1.42	4 Years
Prospective cohort study to determine the association of pre-operative nutritional status with 90 days morbidity among patients undergoing Radical cystectomy or Radical Cysto-Prostatectomy for Bladder Cancer	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	.11	4 Years 5 Months

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

REGISTRAR of HBNI

होमी भाभा राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean - Academic of the various departments of HBNI

Pilot Study to standardize the technique of Dynamic Sentinel Lymph Node Biopsy in management of penile cancer patients with clinically normal groin	Dr. Gagan Prakash	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.87	3 Years
Effect of intravenous iodinated contrast media on renal function in adults with estimated glomerular filtration rate <45 mL/min/1.73m ² : A randomized controlled non-inferiority trial	Dr. Akshay Baheti	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	62.01	4 Years
Biomarker-based optimization of adjuvant therapy in glioblastoma	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	270.90	5 Years
A Pilot Study of CONcurrent ChEMotherapy and RadioTherapy in Adjuvant Treatment of Breast Cancer (CONCERT)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	6.66	5 Years
Rapid Palliation in Locally Advanced Cervical Cancer: A Phase III randomized trial (RAPPAL Study)	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	71.52	5 Years
Inflammatory Indices in Diffuse Glioma (InDiGo): A Prospective Observational Study	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	3.57	6 Years
Androgen blockade - Is this the missing link between mucinous micro-papillary carcinoma and micro-papillary carcinoma of breast.	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	40.57	4 Years
A Prospective Randomised trial to assess the clinical utility of TMH Mini Quality of Life (TMQ) questionnaire	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.00	3 Years
HIPEC after Neoadjuvant Chemotherapy in Frontline Treatment of Advanced Epithelial Ovarian, Fallopian tube or Primary Peritoneal Cancer: A Phase III Randomized Controlled Trial	Dr. Amita Maheshwari	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	253.35	6 Years
Clinical effect of vaporized CAnnabinoids on BREast cancer genetic EXpression patterns in the peri-operative period (CABREX study)	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	68.70	4 Years
A phase II study of hormone therapy alone in low-grade serous cancer (ovary/fallopian tube/peritoneum) following debulking surgery	Dr. Seema Gulia	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	25.50	6 Years
Prevalence of cardiovascular diseases in long term Breast Cancer survivors	Dr. Sheela Sawant	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	20.64	6 Years
Phase III, Assessor blinded, randomised controlled trial of the use of intraoperative neuromonitoring (IONM) in thyroid cancer surgery	Dr. Gouri Pantvaidya	TERRY FOX	Non-Government	Medical & Health Sciences	2019	30.09	5 Years
Establishing an in house, cost effective, TMH Predict gene panel for Prognosis and Prediction in Breast Cancer Patients subjected to adjuvant therapy.	Dr. Omshree Shetty	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	21.50	3 Years
A Prospective Phase III open label Randomized Controlled Trial evaluating the role of Neo-adjuvant chemotherapy in mandible preservation in oral cavity cancers	Dr. Devendra Chaukar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	377.59	6 Years

डॉ. पी. सी. सेल्विन / Prof. P. C. Selvin

REGISTRAR

Office of HBNZ

PJOM SHABHA NATIONAL INSTITUTE

शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 004

Compilation of data as received from Dean, Academic of the

Dose Escalated Radiotherapy and Organ Preservation in Rectal Cancers (DEROP-RC)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	28.57	4 Years
Neoadjuvant treatment versus upfront surgery in Resectable pancreatic cancer (NEVUS)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	74.40	5 Years
A double arm, phase-III randomised study to assess the effect of Resveratrol-Copper in reducing oral mucositis in patients receiving concurrent chemo-radiotherapy for locally advanced oral cavity and oropharyngeal cancers	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	51.55	5 Years
A Prospective Randomized Phase III Trial of Short Course Versus Long Course Local Radiotherapy in patients with Multiple Myeloma symptomatic for Pain (ProM)	Dr. Nehal Khanna	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	81.51	6 Years
PREcedeNT trial: Phase III randomised-controlled open-label trial of Lutetium - 177 Peptide Receptor Radionuclide Therapy (PRRT) Plus Chemotherapy Versus PRRT alone in FDG-avid, Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETS)	Dr. Ameya Puranik	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	24.00	8 Years
Effect of nurse led intervention on cognitive and non-cognitive functions and serum TNF alpha levels in patients receiving chemotherapy for CRC at Tata Memorial Hospital, Mumbai	Mrs. Anita D Souza	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	15.87	3 Years
Classical Hodgkins lymphoma(CHL) with primary marrow presentation- does it use immune escape mechanism to hide ?	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	6.12	1 Years
A prospective study to evaluate the Adverse Drug Reactions and to assess quality of life in prostate cancer patients receiving docetaxel in Tata Memorial Centre.	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	10.42	4 Years
Prevalence and impact of Vitamin D deficiency on the treatment outcomes of Head and Neck squamous cell carcinoma patients.	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	30.00	4 Years
Assessment of financial burden in patients with head and neck cancer undergoing curative intent treatment	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.00	3 Years 9 Months
Evaluation of Organ filling (rectum and bladder) and Comprehensive Adaptive Radiotherapy using daily imaging by CBCT during radical radio(chemo)therapy for locally advanced cervical cancers.	Dr. Lavanya G	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	35.12	3 Years 6 Months
Intra-operative recurrent laryngeal nerve monitoring during three field esophagectomy- a pilot study	Dr. Sabita Jiwnani	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	11.92	3 Years

Compilation of data as received from Dean- Academic of the *Prof. P. S. Bhatnagar / Prof. B. G. Sawant* B.N.I.

कलर्स विल / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशास्त्री नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

A study of factors associated with delayed presentation of patients with Testicular Germ Cell Tumors for seeking specialized care at Tata Memorial Hospital. (DeLP-GCT)	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	.10	4 Years
A prospective pilot study to evaluate the success of LYMPHA (Lymphatic Microsurgical Preventive Healing Approach) in women undergoing Axillary dissection for breast cancer	Dr. Vinay Shankhdhar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	2.54	3 Years
Impact of Tumor Bed Boost Technique on Toxicity and Aesthetic Outcomes after Breast Conservation Therapy: A Prospective Longitudinal Study	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	9.85	5 Years
Patient perception of 'meaningful benefit' from palliative chemotherapy in metastatic lung cancer - A survey	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	2.15	4 Years
A Prospective, Observational study to Compare Quality of Life and side effects in patients undergoing Medical versus Surgical Castration in Metastatic Carcinoma of Prostate at Tata Memorial Hospital	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	12.22	4 Years
Development and Implementation of Artificial Intelligence Technology for Validated Risk Prediction Model for Different Stages of Oral Cavity Squamous Cell Carcinoma	Dr. Pankaj Chaturvedi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	73.60	3 Years
Phase 1 study of safety and feasibility of Ayurvedic oral cannabis preparation in the peri-operative period in oral cavity squamous cell cancer	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	86.56	2 Years
Growth, Endocrine And Reproductive Late Effects In Long-Term Survivors Of Childhood Cancers: A Prospective Observational Study	Dr. Maya Prasad	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	26.59	5 Years
Assessment of Surgical margins in BCS using Intraoperative imaging Techniques (ASSIST)	Dr. Nita Nair	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	5.39	3 Years
A randomized controlled trial to Assess the incidence of lymphedema in women with breast cancer undergoing Sentinel lymph node biopsy or Low axillary sampling. (AiSLe)	Dr. Nita Nair	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	9.92	3 Years
A study evaluating the efficacy of axillary reverse mapping in biopsy proven patients undergoing upfront surgery.	Dr. Vani Parmar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	2.90	3 Years
Study of the excess cost associated with drug wastage due to limited vial size options of the intravenous drugs for anti-cancer treatment, among patients receiving such treatment at Tata Memorial Hospital - 'CADWIACT' study	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	0.6	2 Years 6 Months

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 REGISTRAR / DEAN
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Deam - Academic of the

To assess the efficacy of low dose Abiraterone (250 mg (1 tablet) once daily taken along with food) in comparison to the standard dose Abiraterone (1000 mg (4 tablets) taken in fasting state) in patients with Metastatic Castrate Resistant Prostate Cancer.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	36.35	5 Years
A prospective study to assess the effect of peri operative administration of oral Resveratrol and copper(R- Cu)on survival in Glioblastoma (GBM) patients.	Dr. Aliasgar Moiyadi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	22.64	5 Years
Correlation of O6-Methyl(Alkyl) Guanine-DNA Methyl(Alkyl) Transferase (MGMT/AGAT) Gene Polymorphisms with Hematological Toxicity of Temozolomide in Adult Diffuse Glioma (MAGENTA study)	Dr. Tejal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	1.69	3 Years
A study to validate the Multinational Association of Supportive Care in Cancer (MASCC) antiemesis tool for adolescent and adult patients with hematological malignancies receiving chemotherapy.	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	0.27	2 Years 6 Months
Improving the efficiency of Breath-hold treatment in cancer radiotherapy using 3D goggles: a randomized study	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	9.75	3 Years
Pregabalin for chronic cough in patients with lung cancer: A randomized double-blind placebo-controlled trial.	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	12.58	2 Years
Establishment of surveillance system for individuals diagnosed with SARS-CoV-2.	Dr. Rajesh Dikshit	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	20.00	1 Years
Intravesical BCG: is the urinary bladder ready to receive it?	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	21.58	1 Years
Efficacy of Lutetium 177 DOTA TATE (Peptide (somatostatin) Receptor Radionuclide Therapy -PRRT) in relapsed high risk Neuroblastoma patients : A phase II study.	Dr. Sneha Shah	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	59.56	2 Years
Prospective study to evaluate which method of estimated GFR best predicts for measured GFR in patients with ovarian cancer undergoing carboplatin based chemotherapy	Dr. Jaya Ghosh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	2.37	2 Years
Randomized control trial to test Pre-exposure prophylaxis (PREP) with oral Acyclovir to prevent chickenpox in varicella-seronegative children with hematolymphoid malignancies receiving intensive chemotherapy at Tata Memorial Hospital	Dr. Chetan Dhamne	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	28.79	2 Years
Posterior fossa Ependyomas: a study on molecular subgrouping	Dr. Sridhar Epari	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	27.97	2 Years
Treating children with relapsed ALL with mitoxantrone based protocol- A prospective observational study	Dr. Nirmalya Moulik	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	15.61	5 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR

होमि भट्टा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean - Academic of the various

Evaluation of PDL1 Antibody SP142 in Triple Negative Breast Cancer (TNBC)	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	8.18	1 Years
National Quality Assurance (NQA) program in Biochemistry for Electrophoresis, Immunofixation and Tumor markers in centers of the National Cancer Grid	Dr. Kinjalika Ghosh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	60.52	3 Years
PROspective Study on the use of gERiatric assessment Tools for validation of 1-year mortality in breast cancer patients 65 years and older (PROTECT)	Dr. Tabassum Wadavaniwala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	10.20	3 Years
Prostate Health Index (PHI) - Is it a Master Key for Diagnosis of Prostate Cancer?	Dr. Kinjalika Ghosh	Beckman Coulter Pvt. Ltd.	Non-Government	Medical & Health Sciences	2021	23.00	2 Years
Assessment of the Breast Cosmesis using Deep neural networks: an exploratory study (ARCD)	Dr. Tabassum Wadavaniwala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	10.20	3 Years
To Study the Challenges in implementing the government funded health schemes for the treatment of cancer patients in Tata Memorial Centre, Mumbai.	Dr. Atul Budukh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	9.05	1 Years 6 Months
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Dr. Badira Parambil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	53.53	10 Years
Pilot testing of Hindi and Marathi translations of the European Organization for the Research and Treatment of Cancer (EORTC) module, assessing quality of life in patients with primary vulva cancer (EORTC QLQ-VU34)	Dr. Suorlya Choora	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.1	1 Years 6 Months
Clinicopathological Review of Breast Carcinoma with Lobular Features	Dr. Sangeeta Desai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	2.71	1 Years
Ambispective registry of oligometastatic and oligorecurrent head and neck cancer patients treated at Tata Memorial Hospital.	Dr. Monali Swain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	23.23	5 Years

Compilation of data as received from Dean-Academics of various CI's/OCC of HBNI.


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Retrospective Evaluation of Immunohistochemical 'Histone modifying' epigenetic underpinnings of Breast carcinomas	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	13.74	1 Years
Effect of Terlipressin in Patients Undergoing Major Hepatectomies for Liver Cancers: A Prospective Randomized Controlled Phase-III Trial (TerliHep Trial)	Dr. Sohan Solanki	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	25.69	4 Years
Clinical outcomes and quality of life in patients with locally advanced vulvovaginal cancers: Ambispective registration study.	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	5.99	5 Years
Correlation of O6 -Methyl(Alkyl) Guanine-DNA Methyl(Alkyl) Transferase (MGMT/AGAT) Gene Polymorphisms with Hematological Toxicity of Temozolomide in Adult Diffuse Glioma (MAGENTA) - A Case-Control study	Dr. Tejal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	5.29	2 Years
Developing a 3D-printed Humanoid Phantom for Breast Cancer Radiotherapy Dosimetry and Quality Assurance	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.36	2 Years
Three field radical esophagectomy versus two field esophagectomy a prospective randomized controlled trial	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2004	37.64	18 Years
A prospective randomized trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IB3 squamous carcinoma of the uterine cervix	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2003	63.16	19 Years 5 Months 20 Days
Phase III trial of surgery followed by conventional radiotherapy (5 fractions/ week) vs concurrent chemoradiotherapy vs accelerated radiotherapy (6 Fractions/week) in high risk, locally advanced stage III & IVA, resectable, squamous cell carcinoma of oral cavity	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2005	38.99	17 Years 5 Months 15 Days

Compilation of data as received from Deam- Academie of the various CI/OCC of HBNI
Rohit

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094